

Reference sample name	Type	Manufacturer	Catalogue number	VAF % tested	Content of reference sample provided by vendor
Twist cDNA Pan-cancer Reference Standard Set	cfDNA	Twist Biosciences	104549	WT (0%), 0.5%, 1%, 2%, 5%	84 Genes - 458 mutations (SNVs, Indels) + 15 fusions
5-Gene-Multiplex - cfDNA product	cfDNA	SensID	SID-000093	WT (0%), 0.5%, 1%, 2%, 5%	5 genes, covering 8 SNVs and INDELS
cfDNA (human) 0% AF Ashkenazim Son	cfDNA	SensID	SID-000003	WT (0%)	Negative Control for EGFR mutations (8), 5-gene multiplex mutations (8) and PIK3CA mutations (11).
cfDNA (human, BDXXP4) 0% AF	cfDNA	SensID	SID-000113	WT (0%)	Negative Control
ESR1 Reference Set 1% AF cfDNA	cfDNA	SensID	SID-000144	1.0%	9 SNVs, spanning within exons 5, 7, and 8 of ESR1 gene.
Multiplex I cfDNA Reference Standard Set	cfDNA	Horizon	HD780	WT (0%), 0.5%, 1%	4 genes, covering 8 SNVs and INDELS
Structural Multiplex cfDNA Reference Standard	cfDNA	Horizon	HD786	5%, 0.5%	14 genes, covering 8 SNVs, 6 INDELS, 2 CNVs, and 2 fusions
OncoSpan cfDNA	cfDNA	Horizon	HD833	N/A	152 key cancer genes - 236 variants with a COSMIC ID and more than 27 INDELS
SeraSeq® cfDNA Complete™ Mutation Mix	cfDNA	SeraCare	0710-0530	0.5%	12 SNVs, 7 Indels, 3 CNVs and 3 fusions in 16 genes
SeraSeq® cfDNA Mutation Mix v2	cfDNA	SeraCare	0710-0140	0.5%	40 genes with 2 fusions
SeraSeq® MSI Reference Panel Mix	gDNA	SeraCare	0710-1675		
SensID MSI/MSS FFPE Reference Set	FFPE	SensID	SID-000139		
SeraSeq® Compromised FFPE Tumor DNA Reference Material	FFPE	SeraCare	0710-1492	N/A	34 variants in 17 genes with all variant types – SNVs (18), INDELS (10), CNVs (3) and SVs (3)

<b>CANCER TYPE</b>	<b>Number of cases (N)</b>
Lung cancer	98
Breast cancer	12
Colon cancer	9
unknown	5
Prostate cancer	5
Pancreatic cancer	3
Melanoma	1
Neuroblastoma	1
Endometrium cancer	1
Primitive unknown	1
Cholangiocarcinoma	1

Sample no	Cancer Type	Alteration type	Gene	cDNA change	Protein change	Other alteration details	Orthogonal test analysis and method	Orthogonal test input (ng)	Orthogonal test observation	HP2 input (ng)	HP2 observation	Additional comments		
1	Lung cancer	SNV	EGFR	c.2573T>G	L858R p.(Leu858Arg)		cfDNA - NGS	36.81	0.23%	30.00	0.65%	-		
		SNV	TP53	c.481G>A	A161T p.(Ala161Thr)		cfDNA - NGS		Not covered		0.48%	-		
2	Lung cancer	INDEL	EGFR	c.2237_2255delinsT	E746_S752delinsV p.(Glu746_Ser752delinsVal)		cfDNA - NGS	66.25	85.51%	30.00	40.90%	-		
		INDEL	EGFR	c.2237_2254del	E746_S752delinsA p.(Glu746_Ser752delinsAla)		cfDNA - NGS		0.11%		0.11%	-		
		SNV	TP53	c.581T>G	L194R p.(Leu194Arg)		cfDNA - NGS		Not covered		44.84%	-		
3	Lung cancer	SNV	KRAS	c.183A>C	G61H p.(Gln61His)		cfDNA - NGS	36.81	1.49%	30.00	3.01%	-		
		SNV	KRAS	c.34G>T	G12C p.(Gly12Cys)		cfDNA - NGS		1.41%		1.43%	-		
		SNV	MET	c.2908C>T	R970C p.(Arg970Cys)		cfDNA - NGS		Not covered		60.35%	-		
4	Lung cancer	SNV	MET	c.3028+1G>T	X1010_splice		cfDNA - NGS	62.50	Not covered	30.00	29.79%	-		
		SNV	TP53	c.817C>T	R273C p.(Arg273Cys)		cfDNA - NGS		Not covered		16.93%	-		
		SNV	TP53	c.839G>A	R280K p.(Arg280Lys)		cfDNA - NGS		Not covered		0.93%	-		
5	Lung cancer	SNV	GNAS	c.602G>A	R201H p.(Arg201His)		cfDNA - NGS	50.00	Not detected at 1%	40.00	0.46%	Orthogonal assay has only 1% of LoQ for the GNAS mutation		
6	Lung cancer	INDEL	TP53	c.403del	C135Afs*35 p.(Cys135Afs*35)		cfDNA - NGS	100.00	6.50%	40.00	5%	-		
7	Lung cancer	INDEL	BRAF	c.2128-5_2128-4insT	X710_splice		cfDNA - NGS	54.00	Not covered	40.00	14.67%	-		
8	Lung cancer	SNV	BRAF	c.1801A>G	R601E p.(Leu601Glu)		cfDNA - NGS	37.70	0.60%	13.30	0.86%	-		
9	Lung cancer	INDEL	KRAS	c.34_35delinsTT	G12C p.(Gly12Cys)		cfDNA - NGS	73.75	1.13%	40.00	1.43%	-		
		SNV	MET	c.2908C>T	R970C p.(Arg970Cys)		cfDNA - NGS		Not covered		51.16%	-		
10	Lung cancer	INDEL	EGFR	c.2235_2249del	E746_A750del p.(Glu746_Ala750del)		cfDNA - NGS	73.75	0.44%	40.00	0.75%	-		
11	Lung cancer	INDEL	EGFR	c.2319_2320insTCCCAC	H773_V774insSH p.(His773_Val774insSerHis)		cfDNA - NGS	36.81	86%	35.00	75.75%	-		
		SNV	NTRK1	c.1961G>A	R654R p.(Arg654His)		cfDNA - NGS		Not covered		1.10%	-		
		SNV	TP53	c.375+1G>T	X125_splice		cfDNA - NGS		Not covered		26.76%	-		
12	Lung cancer	SNV	EGFR	-	-	Copy number gain	cfDNA - NGS	-	Not covered	-	GAIN - Fold change - 4.18	-		
		SNV	KRAS	c.163A>G	I65V p.(Ile65Val)		cfDNA - NGS	100.00	3.60%	40.00	2.11%	-		
		SNV	TP53	c.384del	A129Pfs*41 p.(Ala129Pfs*41)		cfDNA - NGS	100.00	0.80%	40.00	1.16%	-		
13	Lung cancer	SNV	PIK3CA	c.1633G>A	E542K p.(Glu542Lys)		cfDNA - NGS	58.60	0.20%	40.00	1.01%	-		
		INDEL	TP53	c.710_716dup	G320Vfs*2 p.(Ser740Valfs*2)		cfDNA - NGS		0.90%		2.35%	-		
		SNV	EGFR	c.2303G>T	S768I p.(Ser768Ile)		cfDNA - NGS		52.80		0.60%	40.00	1.22%	-
14	Lung cancer	SNV	PIK3CA	c.3140A>G	H1047R p.(His1047Arg)		cfDNA - NGS	52.80	1.70%	40.00	3.69%	-		
		SNV	BRAF	c.1406G>C	G469A p.(Gly469Ala)		cfDNA - NGS		0.15%		0.16%	-		
		Fusion	RET-HOOK3	-	-	HOOK3:11;exon-RET:12;exon	cfDNA - NGS		36.81		Not covered	35.00	Supporting reads - 4 confidence score - 84	-
16	Lung cancer	INDEL	BRAF	c.2128-5_2128-4insT	X710_splice		cfDNA - NGS	36.81	Not covered	35.00	23.47%	-		
		SNV	PIK3CA	c.1624G>A	E542K p.(Glu542Lys)		cfDNA - NGS		0.62%		1.20%	-		
		SNV	TP53	c.527G>A	C176Y p.(Cys176Tyr)		cfDNA - NGS		Not covered		2.12%	-		
17	Colon cancer	SNV	KRAS	c.383G>A	G13D p.(Gly13Asp)		cfDNA - NGS	100.00	1.9%	40.00	4.19%	-		
		SNV	BRAF	c.1495A>G	V499E p.(Val499Glu)		cfDNA - NGS		3.70%		3.78%	-		
		MSI	-	-	MSI - High	cfDNA - NGS	100.00		MSI - High detected		MSI - High detected - Score 1	-		
		SNV	GNAS	c.680A>G	Q227R p.(Gln227Arg)		cfDNA - NGS		Not detected at 1%		0.70%	-		
		SNV	KIT	c.1732T>C	Y578H p.(Tyr578His)		cfDNA - NGS		1.20%		3.77%	-		
		SNV	KRAS	c.436G>A	A146T p.(Ala146Thr)		cfDNA - NGS		Not detected		0.48%	-		
18	Lung cancer	SNV	PIK3CA	c.2491C>T	p.(Leu831Phe)		cfDNA - NGS	90.80	0.80%	21.70	Not detected	Low rig starting input for HP2 in library preparation		
		INDEL	EGFR	c.2235_2249del	E746_A750del p.(Glu746_Ala750del)		cfDNA - NGS		8.20%		8.12%	-		
		SNV	TP53	c.824G>A	C275Y p.(Cys275Tyr)		cfDNA - NGS		100.00		8.40%	40.00	7.15%	-
20	Lung cancer	Fusion	EML4-ALK	-	-	EML4:02;exon-ALK:20;exon	FFPE - NGS	-	Fusion not detected by LBx test but confirmed in tissue	-	Supporting reads - 35 confidence score -	-		
		INDEL	EGFR	c.2235_2249del	E746_A750del p.(Glu746_Ala750del)		cfDNA - NGS	35.00	1.89%	35.00	1.93%	-		
		SNV	TP53	c.742C>T	R248W p.(Arg248Trp)		cfDNA - NGS	34.30	0.90%	30.00	0.96%	-		
21	Lung cancer	SNV	BRAF	c.1801A>G	R601E p.(Leu601Glu)		cfDNA - NGS	33.75	0.11%	21.70	0.34%	-		
		INDEL	EGFR	c.2238_2248delinsGC	L747_A750delinsP p.(Leu747_Ala750delinsPro)		cfDNA - NGS		0.76%		0.63%	-		
		SNV	TP53	c.523C>G	R175G p.(Arg175Gly)		cfDNA - NGS		43.75		Not covered	22.40	0.62%	-
23	Lung cancer	SNV	TP53	c.916C>T	R306I p.(Arg306Ile)		cfDNA - NGS	36.81	Not covered	35.00	0.34%	-		
		SNV	TP53	c.798T>C	R269P p.(Arg269Pro)		cfDNA - NGS		Not covered		0.91%	-		
		SNV	KRAS	c.183A>T	G61H p.(Gln61His)		cfDNA - NGS		0.29%		0.37%	-		
		SNV	STK11	c.454C>T	O152I p.(Gln152I)		cfDNA - NGS		Not covered		1.04%	-		
		SNV	KRAS	c.64C>A	Q22K p.(Gln22Lys)		cfDNA - NGS		1.22%		8.48%	-		
		SNV	KIT	c.1553C>T	P518L p.(Pro518Leu)		cfDNA - NGS		36.81		Not covered	35.00	49.18%	-
25	Lung cancer	SNV	ALK	c.4148T>C	L1383T p.(Ile1383Thr)		cfDNA - NGS	66.25	Not covered	40.00	2.37%	-		
		SNV	KRAS	c.183A>C	G61H p.(Gln61His)		cfDNA - NGS		1.17%		2.67%	-		
		SNV	STK11	c.454+1G>T	X155_splice		cfDNA - NGS		Not covered		4.48%	-		
26	Lung cancer	SNV	KRAS	c.34G>T	G12C p.(Gly12Cys)		cfDNA - NGS	66.25	0.21%	40.00	0.41%	-		
		SNV	EGFR	c.2293G>A	V765M p.(Val765Met)		cfDNA - NGS		0.10%		0.29%	-		
		INDEL	FGFR1	c.396_398del	D166del p.(Asp133del)		cfDNA - NGS		36.81		Not covered	35.00	0.18%	-
28	Lung cancer	SNV	STK11	c.1225C>G	R409G p.(Arg409Gly)		cfDNA - NGS	26.00	Not covered	30.00	46.94%	-		
		SNV	KRAS	c.35G>A	G12D p.(Gly12Asp)		cfDNA - NGS		3.50%		3.45%	-		
		MSI	-	-	MSI - High	cfDNA - NGS	100.00		MSI - High detected		MSI - High detected - Score 0.99	-		
30	Lung cancer	INDEL	ERBB2	c.2332_2340dup	G776_P780dup p.(Gly776_Pro780dup)		cfDNA - NGS	100.00	97.70%	40.00	93.1%	-		
		SNV	TP53	c.659A>G	Y220C p.(Tyr220Cys)		cfDNA - NGS		96.50%		96.88%	-		
		SNV	FGFR1	-	-	Copy number loss	cfDNA - NGS		Not covered		LOSS - Fold change - 0.39	-		
31	Lung cancer	SNV	EGFR	c.2573T>G	L858R p.(Leu858Arg)		cfDNA - NGS	36.81	0.23%	30.00	0.38%	-		
		SNV	TP53	c.481G>A	A161T p.(Ala161Thr)		cfDNA - NGS		Not covered		0.73%	-		
		INDEL	EGFR	c.2237_2255delinsT	E746_S752delinsV p.(Glu746_Ser752delinsVal)		cfDNA - NGS		85.51%		40.91%	-		
32	Lung cancer	INDEL	EGFR	c.2237_2254del	E746_S752delinsA p.(Glu746_Ser752delinsAla)		cfDNA - NGS	66.25	0.11%	30.00	0.40%	-		
		SNV	TP53	c.581T>G	L194R p.(Leu194Arg)		cfDNA - NGS		Not covered		46.24%	-		
		SNV	KRAS	c.183A>C	G61H p.(Gln61His)		cfDNA - NGS		36.81		1.49%	30.00	3.00%	-
33	Lung cancer	SNV	KRAS	c.34G>T	G12C p.(Gly12Cys)		cfDNA - NGS	62.50	1.41%	30.00	0.14%	-		
		SNV	MET	c.2908C>T	R970C p.(Arg970Cys)		cfDNA - NGS		Not covered		60.35%	-		
		SNV	MET	c.3028+1G>T	X1010_splice		cfDNA - NGS		Not covered		29.33%	-		
		SNV	TP53	c.817C>T	R273C p.(Arg273Cys)		cfDNA - NGS		Not covered		16.66%	-		
		SNV	TP53	c.839G>A	R280K p.(Arg280Lys)		cfDNA - NGS		Not covered		0.91%	-		
		SNV	KRAS	c.35G>A	G12D p.(Gly12Asp)		cfDNA - NGS		3.50%		3.65%	-		
36	Lung cancer	MSI	-	-	MSI - High	cfDNA - NGS	26.00	MSI - High detected	30.00	MSI - High detected - Score 0.91	-			
		SNV	TP53	c.659A>G	Y220C p.(Tyr220Cys)		cfDNA - NGS	100.00	96.50%	40.00	96.88%	-		
		SNV	FGFR1	-	-	Copy number loss	cfDNA - NGS	Not covered	LOSS - Fold change - 0.39	-				
37	Lung cancer	SNV	EGFR	c.2573T>G	L858R p.(Leu858Arg)		cfDNA - NGS	36.81	0.23%	30.00	0.38%	-		
		SNV	TP53	c.481G>A	A161T p.(Ala161Thr)		cfDNA - NGS		Not covered		0.73%	-		
		INDEL	EGFR	c.2237_2255delinsT	E746_S752delinsV p.(Glu746_Ser752delinsVal)		cfDNA - NGS		85.51%		40.91%	-		
		INDEL	EGFR	c.2237_2254del	E746_S752delinsA p.(Glu746_Ser752delinsAla)		cfDNA - NGS		66.25		0.11%	30.00	0.40%	-
		SNV	TP53	c.581T>G	L194R p.(Leu194Arg)		cfDNA - NGS		Not covered		46.24%	-		
		SNV	KRAS	c.183A>C	G61H p.(Gln61His)		cfDNA - NGS		36.81		1.49%	30.00	3.00%	-
38	Colon cancer	SNV	KRAS	c.34G>T	G12C p.(Gly12Cys)		cfDNA - NGS	100.00	1.41%	30.00	0.14%	-		
		SNV	MET	c.2908C>T	R970C p.(Arg970Cys)		cfDNA - NGS		Not covered		60.35%	-		
		SNV	MET	c.3028+1G>T	X1010_splice		cfDNA - NGS		Not covered		29.33%	-		
		SNV	TP53	c.817C>T	R273C p.(Arg273Cys)		cfDNA - NGS		Not covered		16.66%	-		
		SNV	TP53	c.839G>A	R280K p.(Arg280Lys)		cfDNA - NGS		Not covered		0.91%	-		
		SNV	KRAS	c.35G>A	G12D p.(Gly12Asp)		cfDNA - NGS		3.50%		3.65%	-		
39	Lung cancer	MSI	-	-	MSI - High	cfDNA - NGS	26.00	MSI - High detected	30.00	MSI - High detected - Score 0.91	-			
		INDEL	ERBB2	c.2332_2340dup	G776_P780dup p.(Gly776_Pro780dup)		cfDNA - NGS	100.00	97.70%	40.00	93.1%	-		
		SNV	TP53	c.659A>G	Y220C p.(Tyr220Cys)		cfDNA - NGS	96.50%	96.88%	-				
40	Lung cancer	SNV	EGFR	c.2573T>G	L858R p.(Leu858Arg)		cfDNA - NGS	36.81	0.23%	30.00	0.38%	-		
		SNV	TP53	c.481G>A	A161T p.(Ala161Thr)		cfDNA - NGS		Not covered		0.73%	-		
		INDEL	EGFR	c.2237_2255delinsT	E746_S752delinsV p.(Glu746_Ser752delinsVal)		cfDNA - NGS		85.51%		40.91%	-		
		INDEL	EGFR	c.2237_2254del	E746_S752delinsA p.(Glu746_Ser752delinsAla)		cfDNA - NGS		66.25		0.11%	30.00	0.40%	-
		SNV	TP53	c.581T>G	L194R p.(Leu194Arg)		cfDNA - NGS		Not covered		46.24%	-		
		SNV	KRAS	c.183A>C	G61H p.(Gln61His)		cfDNA - NGS		36.81		1.49%	30.00	3.00%	-
41	Lung cancer	SNV	KRAS	c.34G>T	G12C p.(Gly12Cys)		cfDNA - NGS	62.50	1.41%	30.00	0.14%	-		
		SNV	MET											

Sample ID	Cancer Type	Gene	Variant	Reference	Method	Allele	AF	Supporting Reads	Confidence Score	Other
59	Lung cancer	Fusion	KIF5B:RET	-	-	KIF5B:15:exon-RET:12:exon	cRNA - NGS	Detected - Supporting reads - 1202	30.00	Supporting reads - 42 confidence score - 99
60	Colon Cancer	SNV	PIK3CA	c.1633G>A	E545K p.(Glu545Lys)	cDNA - NGS	N/A	0.50%	30.00	Not detected
61	Lung cancer	SNV	TP53	c.637C>T	R213* p.(Arg213*)	cDNA - NGS	N/A	Not covered	30.00	Sample library preparation QC failed for HP2
62	Lung cancer	INDEL	EGFR	c.2238_2250del	E746_A750del p.(Glu746_Ala750del)	cDNA - NGS	N/A	WT	30.00	WT
63	Endometrium	SNV	TP53	c.733G>A	G235R p.(Glu245Ser)	cDNA - PCR	N/A	Not covered	30.00	0.69%
64	Lung cancer	SNV	TP53	c.1010G>A	R371H p.(Arg371His)	cDNA - PCR	N/A	Not covered	30.00	30.51%
65	Colon Cancer	SNV	TP53	c.817C>T	R273C p.(Arg273Cys)	cDNA - PCR	N/A	Not covered	30.00	31.02%
66	Breast cancer	SNV	TP53	c.499C>T	D167* p.(Gln167*)	cDNA - PCR	N/A	Not covered	30.00	3.61%
67	Neuroblastoma	MSI	-	-	-	MSI - High	cDNA - PCR	MSI - High detected - Score 0.99	30.00	0.25%
68	Lung cancer	SNV	EGFR	-	-	-	cDNA - NGS	Detected - 148 reads	30.00	MSI - High detected - Score 0.99
69	Lung cancer	Fusion	EML4-ALK	-	-	EML4:06:exon-ALK:20:exon	cDNA - NGS	Detected - 148 reads	30.00	Not detected
70	Lung cancer	SNV	TP53	c.819G>A	R273H p.(Arg273His)	cDNA - NGS	50.00	2.49%	30.00	Supporting reads - 57 confidence score - 99%
71	Lung cancer	SNV	PIK3CA	c.1345C>A	P449T p.(Pro449Thr)	cDNA - NGS	50.00	4.20%	30.00	10.06%
72	Lung cancer	SNV	EGFR	c.2573T>G	L858R p.(Leu858Arg)	cDNA - NGS	50.00	7.90%	30.00	Not covered
73	Lung cancer	SNV	KRAS	-	-	-	cDNA - PCR	Not covered	30.00	GAIN - Fold change - 1.82
74	Lung cancer	SNV	MET	-	-	-	cDNA - PCR	Not covered	30.00	GAIN - Fold change - 1.28
75	Lung cancer	SNV	FGFR1	-	-	-	cDNA - PCR	Not covered	30.00	GAIN - Fold change - 1.85
76	Lung cancer	SNV	RET	-	-	-	cDNA - PCR	Not covered	30.00	GAIN - Fold change - 1.38
77	Colon Cancer	Fusion	MET:MET	-	-	MET:13:exon-MET:15:exon	cDNA - PCR	Not covered	30.00	Supporting reads - 18 confidence score - 94%
78	Colon Cancer	SNV	PIK3CA	c.1636C>G	Q546E p.(Gln546Glu)	cDNA - PCR	61.70	Not covered	30.00	0.25%
79	Colon Cancer	SNV	PTEN	c.476G>A	R159K p.(Arg159Lys)	cDNA - PCR	61.70	Not covered	30.00	0.42%
80	Colon Cancer	SNV	KRAS	-	-	-	cDNA - PCR	0.01%	30.00	Not detected
81	Colon Cancer	SNV	NRAS	c.182A>T	G61L p.(Gln61Leu)	cDNA - PCR	61.70	4.68%	30.00	3.67%
82	Breast cancer	SNV	BRAF	c.1906C>T	G636* p.(Gln636*)	cDNA - NGS	61.70	0.54	30.00	1.36%
83	Breast cancer	SNV	KIT	c.710C>T	S24F p.(Ser24Phe)	cDNA - NGS	61.70	0.42%	30.00	0.60%
84	Breast cancer	SNV	KIT	c.1911T>C	V64A p.(Val64Ala)	cDNA - NGS	61.70	0.47%	30.00	0.69%
85	Breast cancer	SNV	PIK3CA	c.1624G>A	E542K p.(Glu542Lys)	cDNA - PCR	61.70	15.93%	30.00	14.93%
86	Breast cancer	SNV	PIK3CA	c.3012G>A	M1004I p.(Met1004Ile)	cDNA - NGS	61.70	15.03%	30.00	14.93%
87	Breast cancer	SNV	PIK3CA	c.3129G>A	M1043I p.(Met1043Ile)	cDNA - NGS	61.70	1.28%	30.00	1.33%
88	Breast cancer	SNV	PTEN	c.389G>A	G127E p.(Gly127Glu)	cDNA - NGS	61.70	0.56%	30.00	0.70%
89	Breast cancer	SNV	PTEN	c.5130C>C	G171H p.(Gln171His)	cDNA - NGS	61.70	0.31%	30.00	0.25%
90	Breast cancer	SNV	TP53	c.994-1G>C	X332_splice	cDNA - NGS	61.70	8.77%	30.00	3.43%
91	Breast cancer	SNV	TP53	c.853G>A	E289K p.(Glu289Lys)	cDNA - NGS	61.70	0.49%	30.00	8.85%
92	Breast cancer	SNV	TP53	c.841G>C	D281H p.(Asp281His)	cDNA - NGS	61.70	0.60%	30.00	0.39%
93	Breast cancer	SNV	TP53	c.524G>A	R175H p.(Arg175His)	cDNA - NGS	61.70	1.01%	30.00	0.99%
94	Breast cancer	SNV	TP53	c.830G>A	C277Y p.(Cys277Tyr)	cDNA - NGS	61.70	0.30%	30.00	1.44%
95	Breast cancer	SNV	HRAS	c.436G>A	A146T p.(Ala146Thr)	cDNA - NGS	61.70	Not covered	30.00	0.12%
96	Breast cancer	SNV	ALK	c.3824G>A	R1275Q p.(Arg1275Gln)	cDNA - NGS	61.70	28.04%	30.00	0.12%
97	Breast cancer	SNV	FGFR1	c.1638C>A	N577K p.(Asn577Lys)	cDNA - NGS	61.70	32.95%	30.00	0.12%
98	Breast cancer	SNV	TP53	c.577C>T	H193Y p.(His193Tyr)	cDNA - NGS	61.70	1.42%	30.00	35.81%
99	Breast cancer	SNV	TP53	c.404G>T	G12C p.(Gly12Cys)	cDNA - NGS	61.70	18.30%	30.00	0.58%
100	Breast cancer	SNV	ERBB2	c.336G>A	R1030Q p.(Arg1030Gln)	cDNA - NGS	61.70	0.74%	30.00	20.18%
101	Breast cancer	SNV	PIK3CA	c.1633G>A	E545K p.(Glu545Lys)	cDNA - NGS	61.70	Not detected	30.00	0.81%
102	Breast cancer	SNV	EGFR	-	-	-	cDNA - PCR	0.05%	30.00	0.16%
103	Breast cancer	SNV	EGFR	-	-	-	cDNA - PCR	Not covered	30.00	0.15%
104	Breast cancer	SNV	ERBB2	-	-	-	cDNA - NGS	GAIN - 3.68 Copies	30.00	GAIN - Fold change - 1.33
105	Breast cancer	SNV	BRAF	-	-	-	cDNA - NGS	Not covered	30.00	GAIN - Fold change - 1.24
106	Breast cancer	SNV	MET	-	-	-	cDNA - PCR	GAIN - 3.68 Copies	30.00	GAIN - Fold change - 1.36
107	Breast cancer	SNV	TP53	c.712T>C	C238R p.(Cys238Arg)	cDNA - PCR	61.70	Not covered	30.00	Not covered
108	Breast cancer	SNV	EGFR	c.2573T>G	L858R p.(Leu858Arg)	cDNA - PCR	61.70	54.30%	30.00	0.37%
109	Breast cancer	SNV	KEAP1	c.1531-2T>G	X511_splice	cDNA - PCR	61.70	Not covered	30.00	9.67%
110	Breast cancer	SNV	TP53	c.375G>T	X125_splice p.(Thr125=)	cDNA - PCR	61.70	Not covered	30.00	1.09%
111	Breast cancer	SNV	KRAS	c.348G>T	G12C p.(Gly12Cys)	cDNA - PCR	61.70	7.60%	30.00	0.01%
112	Breast cancer	SNV	TP53	c.730G>T	G234G p.(Glu244Glu)	FFPE - NGS	61.70	14.93%	30.00	1.68%
113	Breast cancer	SNV	TP53	c.524G>A	R175H p.(Arg175His)	FFPE - NGS	61.70	17.00%	30.00	1.20%
114	Breast cancer	SNV	KRAS	c.35G>C	G12A p.(Gly12Ala)	cDNA - PCR	61.70	1.30%	30.00	1.69%
115	Breast cancer	SNV	MAP2K1	c.129T>G	D43E p.(Asp43Glu)	cDNA - PCR	61.70	Not covered	30.00	0.20%
116	Breast cancer	SNV	EGFR	c.2573T>G	L858R p.(Leu858Arg)	cDNA - PCR	61.70	11.1%	30.00	11.25%
117	Breast cancer	SNV	EGFR	c.249T>G	L83V p.(Leu83Val)	FFPE - NGS	61.70	Not detected	30.00	8.97%
118	Breast cancer	SNV	PIK3CA	c.1624G>A	E542K p.(Glu542Lys)	FFPE - NGS	61.70	17%	30.00	Not detected
119	Breast cancer	SNV	PIK3CA	c.1633G>A	E545K p.(Glu545Lys)	FFPE - NGS	61.70	Not detected	30.00	0.39%
120	Breast cancer	SNV	TP53	c.849C>T	G317* p.(Gln317*)	FFPE - NGS	61.70	8%	30.00	3.29%
121	Breast cancer	SNV	TP53	c.396G>C	K132N p.(Lys132Asn)	FFPE - NGS	61.70	Not detected	30.00	0.27%
122	Breast cancer	SNV	ERBB2	c.336G>A	R1030Q p.(Arg1030Gln)	FFPE - NGS	61.70	Not detected	30.00	0.14%
123	Breast cancer	INDEL	EGFR	c.2238_2250del	E746_A750del p.(Glu746_Ala750del)	cDNA - PCR	61.70	0.05%	30.00	Not detected
124	Breast cancer	SNV	EGFR	c.2369C>T	T790M p.(Thr790Met)	cDNA - PCR	61.70	0.03%	30.00	Not detected
125	Breast cancer	SNV	TP53	c.427G>A	V143M p.(Val143Met)	cDNA - PCR	61.70	Not covered	30.00	0.15%
126	Breast cancer	INDEL	EGFR	c.2240_2257del	L747_P753delinsP p.(Leu747_Pro753delinsSer)	cDNA - PCR	61.70	17.70%	30.00	7.96%
127	Breast cancer	SNV	RET	c.2045C>A	A682D p.(Ala682Asp)	cDNA - PCR	61.70	Not covered	30.00	1.41%
128	Breast cancer	SNV	GNAS	c.602G>A	R201H p.(Arg201His)	cDNA - PCR	61.70	Not covered	30.00	3.68%
129	Breast cancer	SNV	KRAS	c.35G>T	G12V p.(Gly12Val)	cDNA - PCR	61.70	6.40%	30.00	6.48%
130	Breast cancer	SNV	STRK11	c.721G>C	A241P p.(Ala241Pro)	FFPE - NGS	61.70	49%	30.00	2.11%
131	Breast cancer	SNV	KRAS	c.35G>A	G12V p.(Gly12Val)	cDNA - PCR	61.70	26%	30.00	23.1%
132	Breast cancer	SNV	BRAF	c.1798T>A	V600E p.(Val600Glu)	cDNA - PCR	61.70	0.72%	30.00	0.20%
133	Breast cancer	SNV	TP53	c.849G>C	R283P p.(Arg283Pro)	FFPE - NGS	61.70	2%	30.00	0.47%
134	Breast cancer	SNV	TP53	c.455C>T	P152L p.(Pro152Leu)	FFPE - NGS	61.70	Not detected	30.00	0.13%
135	Breast cancer	SNV	TP53	c.96+1G>A	X32_splice	FFPE - NGS	61.70	Not detected	30.00	2.70%
136	Breast cancer	Fusion	ALK:ALK	-	-	ALK:15:exon-ALK:20:exon	FFPE - NGS	Detected - VAF - 82%	30.00	Supporting reads - 270 confidence score - 89
137	Breast cancer	Fusion	FGFR2:TREC	-	-	FGFR2:18:exon-TREC:2:exon	FFPE - NGS	Detected - VAF - 60%	30.00	Supporting reads - 439 confidence score - 69
138	Breast cancer	INDEL	FGFR2	c.543dup	G182Rn*18 p.(Gly182Asp*18)	FFPE - NGS	61.70	15%	30.00	Not detected
139	Breast cancer	Fusion	CCDC6:RET	-	-	CCDC6:08:exon-RET:12:exon	FFPE - NGS	Not covered	30.00	Supporting reads - 12 confidence score - 74
140	Breast cancer	SNV	TP53	c.736A>G	M248I p.(Met248Ile)	FFPE - NGS	61.70	2.20%	30.00	0.60%
141	Breast cancer	SNV	IDH1	c.394C>T	R132C p.(Arg132Cys)	FFPE - NGS	61.70	1.51%	30.00	0.57%
142	Breast cancer	INDEL	EGFR	c.2231_2319dup	N771_H773dup p.(Asn771_His773dup)	FFPE - NGS	61.70	6.50%	30.00	3.83%
143	Breast cancer	INDEL	EGFR	c.2238_2249del	E746_A750del p.(Glu746_Ala750del)	FFPE - NGS	61.70	3.40%	30.00	0.45%
144	Breast cancer	SNV	EGFR	c.2398T>A	C797S p.(Cys797Ser)	FFPE - NGS	61.70	17.10%	30.00	0.90%
145	Primitive unknown	SNV	KRAS	c.35G>A	G12Dp.(Gly12Asp)	FFPE - NGS	61.70	3.70%	30.00	1.45%
146	Lung cancer	Fusion	CD74:ROS1	-	-	CD74:06:exon-ROS1:35:exon	FFPE - NGS	Detected - VAF - 86%	15.00	Detected - VAF - 0.2%
147	Colon Cancer	SNV	TP53	c.472C>T	R158C p.(Arg158Cys)	FFPE - NGS	61.70	Not detected	10.00	0.21%
148	Colon Cancer	SNV	KRAS	c.436G>A	A146T p.(Ala146Thr)	FFPE - NGS	61.70	2.70%	10.00	Not detected
149	Colon Cancer	SNV	GNAS	c.601C>T	R201C p.(Arg201Cys)	FFPE - NGS	61.70	Not covered	10.00	4.92%
150	Colon Cancer	SNV	FGFR1	-	-	-	cDNA - PCR	Not covered	10.00	GAIN - Fold change - 1.2
151	Colon Cancer	SNV	RET	-	-	-	cDNA - PCR	Not covered	10.00	GAIN - Fold change - 1.3
152	Colon Cancer	SNV	TP53	c.814G>A	V272M p.(Val272Met)	FFPE - NGS	61.70	Detected only in tissue by FISH	15.00	Not detected
153	Breast cancer	SNV	FGFR2	-	-	-	cDNA - PCR	Not covered	10.00	48.80%
154	Breast cancer	SNV	PIK3CA	c.1636C>G	Q546K p.(Gln546Lys)	FFPE - NGS	14.30	11%	10.00	GAIN - Fold change - 2.45
155	Breast cancer	SNV	TP53	c.659A>G	Y220C p.(Tyr220Cys)	FFPE - NGS	14.30	12.7%	10.00	13.40%
156	Breast cancer	SNV	FGFR1	-	-	-	cDNA - PCR	Not covered	10.00	GAIN - Fold change - 1.43
157	Breast cancer	SNV	ESR1	c.1607T>C	L538P p.(Leu538Pro)	FFPE - NGS	4.10	Not detected	10.00	0.47%
158	Breast cancer	SNV	ESR1	c.1608T>A	Y537N p.(Tyr537Asn)	FFPE - NGS	4.10	0.50%	10.00	1.02%
159										

		CNV	EGFR	-	-	Copy number gain	cDNA - NGS		CNV Score - 1.17		Not detected	Score reported by orthogonal test is too low for confident reporting of CNV	
94	Prostate cancer	SNV	ALK	c.3637C>A	P1213T p.(Pro1213Thr)		cDNA - NGS		0.10%		0.14%		
		SNV	TP53	c.578A>G	H193R p.(His193Arg)		cDNA - NGS	36.80	0.11%	23.20	Not detected	Low ng starting input for HP2 in library preparation	
95	Melanoma	SNV	GNAQ	c.626A>T	G209L p.(Gln209Leu)		cDNA - NGS		0.38%		0.39%		
		SNV	KEAP1	c.1108T>C	V369A p.(Val369Ala)		cDNA - NGS	50.00	48.24%	30.00	48.94%	-	
		SNV	GNAS	c.602G>A	R201H p.(Arg201His)		cDNA - NGS		Not detected		0.45%	-	
96	Pancreatic cancer	Negative	-	-	WT		cDNA - NGS	31.20		21.40	WT	-	
97	Breast cancer	SNV	ESR1	c.1613A>G	D538G p.(Asp538Gly)		cDNA - NGS	50.00	0.12%	30.00	0.24%	-	
98	Breast cancer	SNV	PIK3CA	c.1633G>A	E545K p.(Glu545Lys)		cDNA - NGS	50.00	0.15%	30.00	Not detected	-	
99	Breast cancer	SNV	FGFR3	c.2150G>A	A171D p.(Asp171Asp)		cDNA - NGS	41.40	43.78%	24.90	43.58%	-	
100	Breast cancer	SNV	PIK3CA	c.1133G>A	R39H p.(Arg39His)		cDNA - NGS		2.50%		2.62%	-	
		SNV	TP53	c.746G>T	R249M p.(Arg249Met)		cDNA - NGS		53.18%		57.29%	-	
		SNV	EGFR	c.3115-1G>A	X1039_splice		cDNA - NGS		2.63%		2.86%	-	
		SNV	BRAF	c.2221G>C	E741Q p.(Glu741Gln)		cDNA - NGS		1.64%		0.72%	-	
		SNV	FGFR2	c.558G>A	M189I p.(Met189Ile)		cDNA - NGS		0.73%		1.06%	-	
		SNV	KEAP1	c.1081G>T	P361S p.(Pro361Ser)		cDNA - NGS		1.50%		1.17%	-	
		SNV	RET	c.2165A>T	K722M p.(Lys722Met)		cDNA - NGS		5.46%		4.33%	-	
		CNV	ERBB2	-	-		Copy number gain	cDNA - NGS	50.00	CNV Score - 4.32	30.00	Not detected	Score reported by orthogonal test is too low for confident reporting of CNV
		CNV	EGFR	-	-		Copy number gain	cDNA - NGS		CNV Score - 4.16		Not detected	Score reported by orthogonal test is too low for confident reporting of CNV
		CNV	FGFR1	-	-		Copy number gain	cDNA - NGS - low pass WGS		Not covered by Lbx kit but confirmed in low pass WGS		GAIN - Fold change - 1.29	-
		CNV	NRAS	-	-		Copy number loss	cDNA - NGS		Not covered		LOSS - Fold change - 0.68	-
		CNV	RET	-	-		Copy number loss	cDNA - NGS		Not covered		LOSS - Fold change - 0.81	-
CNV	TP53	-	-		Copy number loss	cDNA - NGS		Not covered		LOSS - Fold change - 0.82	-		
101	Breast cancer	SNV	PIK3CA	c.3140A>G	H1047R p.(His1047Arg)		cDNA - NGS		Not detected		0.21%	-	
		SNV	TP53	c.374C>A	T129K p.(Thr129Lys)		cDNA - NGS		0.42%		1.49%	-	
		SNV	ROS1	c.4482C>G	L1488V p.(Leu1488Val)		cDNA - NGS	50.00	0.32%	30.00	Not covered	-	
		Fusion	ALK/ALK	-	-	ALK:10:exon-ALK:20:exon		cDNA - NGS		Not detected		Supporting reads - 7 confidence score - 64%	-
102	Breast cancer	SNV	PIK3CA	c.3140A>G	H1047R p.(His1047Arg)		cDNA - NGS		48.48%		53.11%	-	
		SNV	ESR1	c.1609T>A	Y537N p.(Tyr537Asn)		cDNA - NGS		50.50%		56.21%	-	
		SNV	PIK3CA	c.1232G>A	R401Q p.(Arg401Gln)		cDNA - NGS		Not detected		0.32%	-	
		SNV	ESR1	c.1133C>A	L379I p.(Leu379Ile)		cDNA - NGS		11.82%		18.82%	-	
		SNV	ESR1	c.1278C>A	D426E p.(Asp426Glu)		cDNA - NGS		3.90%		2.22%	-	
		SNV	ESR1	c.1068A>G	M357V p.(Met357Val)		cDNA - NGS		1.07%		Not covered	-	
		SNV	ESR1	c.1613A>G	D538G p.(Asp538Gly)		cDNA - NGS	50.00	0.42%	30.00	Not detected	-	
		CNV	ERBB2	-	-		Copy number gain	cDNA - NGS		CNV Score - 7.48		GAIN - Fold change - 1.48	-
		CNV	FGFR1	-	-		Copy number gain	cDNA - NGS		Not covered		GAIN - Fold change - 3.13	-
		CNV	PIK3CA	-	-		Copy number gain	cDNA - NGS		Not covered		GAIN - Fold change - 1.11	-
		CNV	RET	-	-		Copy number gain	cDNA - NGS		Not covered		GAIN - Fold change - 1.56	-
		CNV	NRAS	-	-		Copy number loss	cDNA - NGS		Not covered		LOSS - Fold change - 0.81	-
CNV	TP53	-	-		Copy number loss	cDNA - NGS		Not covered		LOSS - Fold change - 0.91	-		
103	Breast cancer	SNV	PIK3CA	c.3140A>G	H1047R p.(His1047Arg)		cDNA - NGS		25.13%		26.27%	-	
		SNV	TP53	c.773G>A	G732N p.(Arg732Asn)		cDNA - NGS		Not detected		0.32%	-	
		SNV	ESR1	c.1607T>G	L538I p.(Leu538Arg)		cDNA - NGS		0.34%		0.59%	-	
		SNV	ESR1	c.1610A>C	Y537S p.(Tyr537Ser)		cDNA - NGS		1.25%		1.28%	-	
		SNV	ESR1	c.1613A>G	D538G p.(Asp538Gly)		cDNA - NGS		0.45%		0.76%	-	
		SNV	ESR1	c.1609T>A	Y537N p.(Tyr537Asn)		cDNA - NGS	50.00	0.36%	30.00	0.47%	-	
		SNV	ESR1	c.1607T>A	L538I p.(Leu538Arg)		cDNA - NGS		0.13%		0.18%	-	
		SNV	ESR1	c.1607T>C	L538I p.(Leu538Pro)		cDNA - NGS		0.22%		0.24%	-	
		SNV	STK11	c.440G>A	R147H p.(Arg147His)		cDNA - NGS		7.96%		11.76%	-	
		INDEL	PIK3CA	c.2173_2176delinsAATA	D725_E726delinsAATA (p.Arg725_Leu726delinsAAsnLys)		cDNA - NGS		Not covered		16.07%	-	
		SNV	ESR1	c.1138C>G	G1038R p.(Glu1038Arg)		cDNA - NGS		0.09%		Not detected	VAF < 0.1%	
		INDEL	EGFR	c.2235_2249del	E746_A750del p.(Glu746_Ala750del)		cDNA - NGS - CGP	50.00	2.10%	30.00	Not detected	-	
SNV	EGFR	c.2399T>A	C797S p.(Cys797Ser)		cDNA - NGS - CGP		1.90%		1.77%	-			
INDEL	EGFR	c.2235_2249del	E746_A750del p.(Glu746_Ala750del)		cDNA - NGS - CGP		16.80%		13.67%	-			
SNV	PIK3CA	c.1624G>A	E542K p.(Glu542Lys)		cDNA - NGS - CGP		0.26%		0.35%	-			
SNV	PIK3CA	c.1633G>A	E545K p.(Glu545Lys)		cDNA - NGS - CGP	50.00	0.70%	30.00	0.37%	-			
SNV	ERBB2	c.5474T>T	G732N p.(Arg732Asn)		cDNA - NGS - CGP		1.90%		1.07%	-			
SNV	PTEN	c.287C>A	P96Q p.(Pro96Gln)		cDNA - NGS - CGP		0.18%		Not detected	-			
SNV	TP53	c.455C>T	P152L p.(Pro152Leu)		cDNA - NGS - CGP		4.90%		7.29%	-			
SNV	EGFR	c.2573T>G	L858R p.(Leu858Arg)		cDNA - NGS - CGP	50.00	0.13%	30.00	Not detected	-			
SNV	TP53	c.749C>T	P250L p.(Pro250Leu)		cDNA - NGS - CGP		0.07%		0.15%	-			
INDEL	EGFR	c.2235_2249del	E746_A750del p.(Glu746_Ala750del)		cDNA - NGS - CGP		0.10%		0.34%	-			
SNV	ERBB2	c.5254T>C	G732S p.(Arg732Ser)		cDNA - NGS - CGP	50.00	Not detected	27.30	0.16%	-			
SNV	TP53	c.730G>A	G245S p.(Gly245Ser)		cDNA - NGS - CGP		0.22%		0.19%	-			
INDEL	EGFR	c.2235_2249del	E746_A750del p.(Glu746_Ala750del)		cDNA - NGS - CGP	50.00	Not detected	24.50	0.14%	-			
INDEL	EGFR	c.2235_2249del	E746_A750del p.(Glu746_Ala750del)		cDNA - NGS - CGP		4.20%		3.86%	-			
SNV	TP53	c.1182A>G	p.394WexT9		cDNA - NGS - CGP	50.00	0.21%	30.00	Not detected	-			
SNV	TP53	c.473G>A	p.R158H		cDNA - NGS - CGP		0.11%		Not detected	-			
SNV	TP53	c.810G>T	R273M p.(Arg273Met)		cDNA - NGS - CGP		1.00%		1.00%	-			
SNV	ERBB2	c.309G>A	R103Q p.(Arg103Gln)		cDNA - NGS - CGP		Not detected		0.13%	-			
SNV	PIK3CA	c.241G>A	E81K p.(Glu81Lys)		cDNA - NGS - CGP		Not detected		0.12%	-			
SNV	RET	c.2092G>C	D698H p.(Asp698His)		cDNA - NGS - CGP	50.00	0.40%	30.00	0.42%	-			
SNV	IDH2	c.418C>T	p.R140W		cDNA - NGS - CGP		0.20%		Not detected	-			
SNV	TP53	c.469G>T	V157F p.(Val157Phe)		cDNA - NGS - CGP		5.50%		6.67%	-			
SNV	EGFR	c.2573T>G	L858R p.(Leu858Arg)		cDNA - NGS - CGP		0.72%		0.30%	-			
SNV	ALK	c.338G>A	E1129K p.(Glu1129Lys)		cDNA - NGS - CGP		Not detected		0.33%	-			
SNV	PIK3CA	c.1633G>A	E545K p.(Glu545Lys)		cDNA - NGS - CGP	50.00	0.76%	8.40	Not detected	Low ng starting input for HP2 in library preparation			
SNV	PDGFRA	c.2482T>A	R817N p.(Ile817Asn)		cDNA - NGS - CGP		Not detected		0.29%	-			
INDEL	EGFR	c.2235_2249del	E746_A750del p.(Glu746_Ala750del)		cDNA - NGS - CGP	50.00	2.10%	30.00	1.72%	-			
INDEL	TP53	c.816T>G	R273S p.(Arg273Ser)		cDNA - NGS - CGP		2.10%		1.72%	-			
INDEL	EGFR	c.2235_2249del	E746_A750del p.(Glu746_Ala750del)		cDNA - NGS - CGP		1.80%		1.16%	-			
INDEL	FGFR1	c.396_398del	D166del p.(Asp133del)		cDNA - NGS - CGP		Not detected		0.25%	-			
SNV	ERBB2	c.2780G>T	E930D p.(Glu930Asp)		cDNA - NGS - CGP	50.00	50.10%	12.60	50.0%	-			
INDEL	TP53	c.823del	C275Vfs*70 p.(Cys275Valfs*70)		cDNA - NGS - CGP		0.80%		1.15%	-			
CNV	FGFR3	-	-		Copy number gain	cDNA - NGS - CGP		GAIN - Fold change - 1.4		GAIN - Fold change - 1.24	-		
CNV	PIK3CA	-	-		Copy number gain	cDNA - NGS - CGP		fold change 1.353		Not detected	-		
CNV	BRAF	-	-		Copy number gain	cDNA - NGS - CGP		fold change 1.233		Not detected	-		
INDEL	EGFR	c.2235_2250del	E746_A750del p.(Glu746_Ala750del)		cDNA - NGS - CGP	50.00	19.40%	30.00	17.76%	-			
SNV	TP53	c.742C>T	R248W p.(Arg248Trp)		cDNA - NGS - CGP		22.80%		20.23%	-			
SNV	TP53	c.376-1G>T	X126_splice		cDNA - NGS - CGP		Not detected		0.31%	-			
SNV	BRAF	c.1799T>A	V600E p.(Val600Glu)		cDNA - NGS - CGP		0.90%		Not detected	-			
SNV	PIK3CA	c.344G>A	R115Q p.(Arg115Gln)		cDNA - NGS - CGP		Not detected		0.30%	-			
SNV	BRAF	c.1799T>A	V600E p.(Val600Glu)		cDNA - NGS - CGP	50.00	0.39%	30.00	0.21%	-			
SNV	EGFR	c.2573T>G	L858R p.(Leu858Arg)		cDNA - NGS - CGP		1.40%		1.05%	-			
SNV	TP53	c.524G>A	R175H p.(Arg175His)		cDNA - NGS - CGP		Not detected		0.14%	-			
SNV	TP53	c.827C>A	A276D p.(Ala276Asp)		cDNA - NGS - CGP	50.00	Not detected	30.00	0.13%	-			
INDEL	TP53	c.826_827delinsAA	A276N p.(Ala276Asn)		cDNA - NGS - CGP		Not detected		2.38%	-			
CNV	FGFR3	-	-		Copy number gain	cDNA - NGS - CGP		fold change 1.173		Not detected	-		
SNV	FGFR2	c.1085C>T	A362V p.(Ala362Val)		cDNA - NGS - CGP		Not detected		0.38%	-			
SNV	EGFR	c.2573T>G	L858R p.(Leu858Arg)		cDNA - NGS - CGP	50.00	0.40%	7.32	Not detected	Low ng starting input for HP2 in library preparation			
SNV	MARCK1	c.631G>A	V211I p.(Val211Ile)		cDNA - NGS - CGP		Not detected		0.45%	-			
SNV	TP53	c.838A>G	R280Q p.(Arg280Gln)		cDNA - NGS - CGP		Not detected		0.47%	-			
SNV	EGFR	c.2573T>G	L858R p.(Leu858Arg)		cDNA - NGS		74.86%		74.26%	-			
SNV	TP53	c.733G>A	G245S p.(Gly245Ser)		cDNA - NGS		32.02%		29.32%	-			
CNV	PIK3CA	-	-		Copy number gain	cDNA - NGS		Not covered		GAIN - Fold change - 1.22	-		
CNV	EGFR	-	-		Copy number gain	cDNA - NGS		CNV Score - 9.96		GAIN - Fold change - 3.3	-		
CNV	ERBB2	-	-		Copy number gain	cDNA - NGS		CNV Score - 8.48		Not detected	-		
SNV	MET	c.1279G>A	V427I p.(Val427Ile)		cDNA - NGS	50.00	0.86%	30.00	0.41%	-			
SNV	NTRK1	c.1											

Sample ID	Cancer Type	Variant	Gene	Effect	Method	Value	Confidence	Supporting Reads	Other
123	Lung cancer	SNV MET c.3682G>C	D1228H p.(Asp1228His)		cDNA - NGS	46.21%	30.00	46.36%	-
		SNV MET c.3682G>T	D1228Y p.(Asp1228Tyr)		cDNA - NGS	3.13%		3.18%	-
		SNV MET c.3688T>C	Y1230H p.(Tyr1230His)		cDNA - NGS	1.01%		1.01%	-
		SNV MET c.3699A>G	Y1230C p.(Tyr1230Cys)		cDNA - NGS	0.04%		Not detected	VAF <0.1%
		SNV MET c.3286G>T	G1090C p.(Gly1090Cys)		cDNA - NGS	Not detected		3.42%	-
INDEL EGFR c.2240_2257del	L747_P753delinsS p.(Leu747_Pro753delinsSer)		cDNA - NGS	61.92%		61.92%	-		
124	Lung cancer	SNV TP53 c.372C>A	C124* p.(Cys124*)		cDNA - NGS	69.39%		70.10%	-
		SNV EGFR c.2573T>G	L858R p.(Leu858Arg)		cDNA - NGS	60.90%		61.47%	-
		SNV MET c.2923G>A	E979K p.(Glu979Lys)		cDNA - NGS	Not detected		45.71%	-
		SNV ERBB2 c.976G>A	D326N p.(Asp326Asn)		cDNA - NGS	Not detected		0.26%	-
		CNV ALK -	-	Copy number gain	cDNA - NGS	Not covered		GAIN - Fold change - 1.43	-
		CNV ERBB2 -	-	Copy number gain	cDNA - NGS	Not detected		GAIN - Fold change - 1.48	-
		CNV MET -	-	Copy number gain	cDNA - NGS	Not detected		GAIN - Fold change - 1.84	-
		CNV EGFR -	-	Copy number gain	cDNA - NGS	Not detected		GAIN - Fold change - 2.28	-
		SNV EGFR c.2573T>G	L858R p.(Leu858Arg)		cDNA - NGS	0.29%		0.16%	-
		SNV TP53 c.747G>T	R248S p.(Arg248Ser)		cDNA - NGS	0.09%		Not detected	VAF <0.1%
125	Lung cancer	SNV TP53 c.375G>T	S33_1125del p.(Thr1125=)		cDNA - NGS	Not detected		0.46%	-
		SNV PTEN c.493G>A	G165R p.(Gly165Arg)		cDNA - NGS	Not covered		13.78%	-
		SNV PTEN c.138C>G	Y46* p.(Tyr46*)		cDNA - NGS	Not covered		16.72%	-
		SNV EGFR c.2218A>G	T740V p.(Ile740Val)		cDNA - NGS	0.03%		Not detected	VAF <0.1%
		SNV KRAS c.181C>A	G61V p.(Gln61Val)		cDNA - NGS	13.95%		16.07%	-
126	Lung cancer	SNV TP53 c.843C>G	D281E p.(Asp281Glu)		cDNA - NGS	17.36%		18.36%	-
		SNV ERBB2 c.308G>T	R103L p.(Arg103Leu)		cDNA - NGS	Not detected		0.17%	-
		SNV BRCA1 c.2185G>A	E729K p.(Glu729Lys)		cDNA - NGS	47%		Not covered	-
		SNV BRCA1 c.2185G>A	E729K p.(Glu729Lys)		cDNA - NGS	47%		Not covered	-
		SNV ALK -	-	Copy number gain	cDNA - NGS	Not detected		0.17%	-
127	Prostate cancer	SNV GNAS c.603G>A	R201H p.(Arg201His)		cDNA - NGS	Not detected		0.44%	-
		SNV TP53 c.726C>G	C242W p.(Cys242Trp)		cDNA - NGS	Not detected		0.20%	-
		INDEL BRAF c.1458_1472del	N486_T491delinsK p.(Asn486_Thr491delinsLys)		cDNA - NGS	Not detected		0.95%	-
		SNV EGFR c.442G>A	V148M p.(Val148Met)		cDNA - NGS	0.15%		Not detected	-
		INDEL KRAS c.531_533del	K180del p.(Lys180del)		cDNA - NGS	Not detected		44.61%	-
128	Prostate cancer	CNV EGFR -	-	Copy number gain	cDNA - NGS	Not detected		44.61%	-
		CNV MET -	-	Copy number gain	cDNA - NGS	Not detected		GAIN - Fold change - 1.91	-
		SNV TP53 c.527G>A	C178Y p.(Cys178Tyr)		cDNA - NGS	Not detected		GAIN - Fold change - 3.39	-
		SNV MET c.50C>A	T17N p.(Thr17Asn)		cDNA - NGS	Not detected		43.31%	-
		INDEL EGFR c.2240_2257del	L747_P753delinsS p.(Leu747_Pro753delinsSer)		cDNA - NGS	54.32%		58.54%	-
129	Prostate cancer	SNV EGFR c.2582T>A	L861Q p.(Leu861Gln)		cDNA - NGS	4.88%		5.65%	-
		SNV BRAF G466V			cDNA - NGS	0.02%		Not detected	VAF <0.1%
		SNV EGFR c.2389G>T	T790M p.(Thr790Met)		cDNA - NGS	1.90%		1.90%	-
		CNV ERBB2 -	-	Copy number gain	cDNA - NGS	Not covered		Score reported by orthogonal test is too low for confident reporting of CNV	-
		SNV DPYD c.2846A>T	D949V p.(Asp949Val)		cDNA - NGS	0.11%		Not detected	-
130	Lung cancer	INDEL EGFR c.2237_2254del	E746_S752delinsA p.(Glu746_Ser752delinsAla)		cDNA - NGS	2.40%		0.91%	-
		CNV EGFR1 -	-	Copy number gain	cDNA - NGS	Not covered		GAIN - Fold change - 1.24	-
		SNV TP53 c.375+5G>T	X125_splice		cDNA - NGS	Not covered		15.51%	-
		CNV EGFR -	-	Copy number gain	cDNA - NGS	Not covered		16.15%	-
		CNV MET -	-	Copy number gain	cDNA - NGS	Not covered		15.51%	-
131	Lung cancer	Fusion EML4-ALK -	-	EML4:13:exon-ALK:20:exon	cDNA - NGS	Not detected		Supporting reads - 750 confidence score - 99	-
		SNV TP53 c.574C>T	Q192* p.(Gln192*)		cDNA - NGS - CGP	Detected - VAF - 1.4%	30.00	4.50%	Supporting reads - 198 confidence score - 99
		Fusion EML4-ALK -	-	EML4:13:exon-ALK:20:exon	cDNA - NGS - CGP	Detected - VAF - 3.7%		2.39%	Supporting reads - 1103 confidence score - 99
		SNV TP53 c.853G>A	E289K p.(Glu289Lys)		cDNA - NGS - CGP	12.10%		12.38%	-
		CNV EGFR -	-	Copy number gain	cDNA - NGS - CGP	Fold change - 1.195		Not detected	Score reported by orthogonal test is too low for confident reporting of CNV
132	Lung cancer	INDEL BRAF c.2128-5del	X710_splice		cDNA - NGS - CGP	Not detected		1.56%	-
		Fusion EML4-ALK -	-	EML4:20:exon-ALK:20:exon	cDNA - NGS - CGP	Detected - VAF - 7.5%		Supporting reads - 1549 confidence score - 99	-
		CNV EGFR -	-	Copy number gain	cDNA - NGS - CGP	Fold change - 1.46		GAIN - Fold change - 1.29	-
		CNV PIK3CA -	-	Copy number loss	cDNA - NGS - CGP	Not detected		LOSS - Fold change - 0.79	-

Sample number	Sample type	Cancer type	MSI status determined by orthogonal method	Orthogonal MSI status determination method
1	FFPE	CRC	MSI -High	Fragment analysis - Sanger seq - 5 markers
2	FFPE	Lung	MSS	N/A
3	FFPE	Lung	MSS	N/A
4	FFPE	Lung	MSS	N/A
5	FFPE	Metastatic adenocarcinoma	MSS	N/A
6	FFPE	CRC	MSI-High	Fragment analysis - Sanger seq - 5 markers
7	FFPE	CRC	MSI-High	Fragment analysis - Sanger seq - 5 markers
8	FFPE	N/A	MSS	Fragment analysis - Sanger seq - 5 markers
9	FFPE	CRC	MSI-High	Fragment analysis - Sanger seq - 5 markers
10	gDNA	CRC	MSS	Fragment analysis - Sanger seq - 5 markers
11	FFPE	CA endometrium	MSI-High	Fragment analysis - Sanger seq - 5 markers
12	gDNA	CA endometrium	MSS	Fragment analysis - Sanger seq - 5 markers
13	FFPE	CA endometrium	MSI-High	Fragment analysis - Sanger seq - 5 markers
14	gDNA	CA endometrium	MSS	Fragment analysis - Sanger seq - 5 markers
15	FFPE	Spindle cell sarcoma	MSS	Fragment analysis - Sanger seq - 5 markers
16	FFPE	CRC	MSS	Fragment analysis - Sanger seq - 5 markers
17	FFPE	CRC	MSI-High	Fragment analysis - Sanger seq - 5 markers
18	gDNA	CRC	MSS	Fragment analysis - Sanger seq - 5 markers
19	FFPE	CA endometrium	MSS	Fragment analysis - Sanger seq - 5 markers
20	FFPE	Cholangiocarcinoma	MSS	Fragment analysis - Sanger seq - 5 markers
21	FFPE	Metastatic pulmonary adenocarcinoma	MSS	N/A
22	FFPE	Lung	MSS	N/A
23	FFPE	GIST	MSS	N/A
24	FFPE	Lung	MSS	N/A
25	FFPE	Breast	MSS	N/A

Gene_ID	SNV/Indel regio	CNV	Fusions	Transcript - GRCh38
AKT1	Ex 4	-	-	NM_001382430.1
ALK	Full CDS	Yes	Yes	NM_004304.5
BRAF	Full CDS	Yes	-	NM_004333.6
EGFR	Full CDS + Part d	Yes	Yes	NM_005228.5
ERBB2	Full CDS	Yes	-	NM_004448.4
ESR1	Ex 5-8	-	-	NM_000125.4
FGFR1	Full CDS	Yes	Yes	NM_023110.3
FGFR2	Full CDS	Yes	Yes	NM_000141.5
FGFR3	Full CDS	Yes	Yes	NM_000142.5
FGFR4	Full CDS	-	-	NM_213647.3
GNA11	Ex 4, 5	-	-	NM_002067.5
GNAQ	Ex 4, 5	-	-	NM_002072.5
GNAS	Ex 8, 9	-	-	NM_000516.7
HRAS	Full CDS	Yes	-	NM_005343.4
IDH1	Ex 4	-	-	NM_005896.4
IDH2	Ex 4	-	-	NM_002168.4
KEAP1	Full CDS	-	-	NM_203500.2
KIT	Full CDS	-	-	NM_000222.3
KRAS	Full CDS	Yes	-	NM_004985.5
MAP2K1	Ex 2-6, 8	-	-	NM_002755.4
MET	Full CDS	Yes	Yes	NM_000245.4
NRAS	Full CDS	Yes	-	NM_002524.5
NTRK1	Ex 13-17	-	Yes	NM_002529.4
NTRK2	Ex 14-19	-	-	NM_006180.6
NTRK3	Ex 15-20	-	-	NM_001012338.3
PDGFRA	Ex 12, 18	-	-	NM_006206.6
PIK3CA	Full CDS	Yes	-	NM_006218.4
PTEN	Full CDS	-	-	NM_000314.8
RET	Full CDS	Yes	Yes	NM_020975.6
ROS1	Ex 36-41	-	Yes	NM_001378902.1
STK11	Full CDS	-	-	NM_000455.5
TP53	Full CDS	Yes	-	NM_000546.6



	<b>NextSeq 500/550</b>	<b>NextSeq 1000/2000</b>	<b>NovaSeq 6000</b>	<b>All</b>
<b>Flow Cell</b>	Mid-output	P1/P2	SP	
<b>N runs</b>	10	7	4	21
<b>N samples</b>	55	50	55	160
<b>Reads [M]</b>	44.33±9.11	59.28±10.46	61.03±12.51	54.74±13.19
<b>Bases [Gb]</b>	6.60±1.36	8.95±1.58	9.70±1.99	8.40±2.14
<b>Aligned duplex consensus reads [M]</b>	1.06±0.26	1.22±0.17	1.29±0.29	1.19±0.27
<b>Duplex consensus reads aligned on target [%]</b>	95.94±1.73	94.94±1.72	97.22±2.04	96.08±2.06
<b>Mean coverage (duplex consensus reads) - from Prime [x]</b>	758.67±187.69	871.28±134.08	944.29±229.54	857.67±204.56
<b>Mean coverage on target (duplex consensus reads) [x]</b>	768.49±190.28	883.13±136.81	959.09±234.42	869.83±208.59
<b>Mean coverage on exons relevant for NSCLC ESCAT Level 1 SNVs/Indels (duplex consensus reads) [x]</b>	957.74±243.11	1012.01±156.54	1119.43±280.00	1030.28±244.07
<b>Fraction of target covered (duplex consensus reads) [%]</b>	100.00±0.01	100.00±0.00	100.00±0.00	100.00±0.00
<b>Coverage evenness [%]</b>	81.96±4.04	86.12±3.48	83.03±4.28	83.63±4.32

	<b>NextSeq 500/550</b>	<b>NextSeq 2000</b>	<b>NovaSeq 6000</b>	<b>All</b>
<b>Flow Cell</b>	Mid-output	P2	SP	
<b>N runs</b>	4	5	2	11
<b>N samples</b>	14	11	12	37
<b>Reads [M]</b>	44.53±2.02	70.41±11.32	60.23±4.94	58.20±12.86
<b>Bases [Gb]</b>	6.63±0.30	10.63±1.71	9.58±0.79	8.92±2.02
<b>Aligned duplex consensus reads [M]</b>	1.23±0.17	1.49±0.10	1.34±0.25	1.35±0.21
<b>Duplex consensus reads aligned on target [%]</b>	96.32±1.21	97.59±0.11	99.39±0.38	97.76±1.49
<b>Mean coverage (duplex consensus reads) - from Prime [x]</b>	891.61±120.73	1094.67±72.32	987.67±178.85	989.88±155.51
<b>Fraction of target covered (duplex consensus reads) [%]</b>	100.00±0.01	100.00±0.00	100.00±0.00	100.00±0.01
<b>Coverage evenness [%]</b>	79.77±2.10	80.72±1.46	79.23±1.98	79.90±1.97

<b>Sample type</b>	<b>Region</b>	<b>Mean coverage (duplex consensus reads) [x]</b>
<b>Clinical cfDNA (N=14)</b>	<b>ESCAT Level 1 for NSCLC</b>	1093±153
	<b>Other target regions</b>	794±111
	<b>All target regions</b>	896±118
<b>cfDNA reference standards (N=23)</b>	<b>ESCAT Level 1 for NSCLC</b>	1206±161
	<b>Other target regions</b>	953±135
	<b>All target regions</b>	1050±145

	<b>NextSeq 2000</b>
<b>Flow Cell</b>	P2
<b>N runs</b>	4
<b>N samples</b>	36
<b>Reads [M]</b>	60.68±11.25
<b>Bases [Gb]</b>	9.16±1.70
<b>Aligned duplex consensus reads [M]</b>	1.27±0.17
<b>Duplex consensus reads aligned on target [%]</b>	95.14±1.56
<b>Mean coverage (duplex consensus reads) - from Prime [x]</b>	899.34±136.38
<b>Fraction of target covered (duplex consensus reads) [%]</b>	100.00±0.00
<b>Coverage evenness [%]</b>	85.99±3.07

Alteration	Alteration details	Alteration type	Relevance for tumor type	Number positives / Number expected	Analytical sensitivity	Observed VAF (median and range)*	Supporting reads depth (median and range)*
<b>ALK SNVs (Acquired resistance kinase domain mutations) (N=5)</b>	2:29416326:G:A (P1543S), 2:29432664:C:T (R1275Q), 2:29436893:C:T, 2:29443695:G:T (F1174L), 2:29445450:C:G (G1128A)	SNVs	NSCLC	50/50	100.00%	0.26% (0.12-0.67%)	6 (3-16)
<b>BRAF V600E</b>	7:140453136:A:T (V600E)	SNVs	NSCLC, CRC, Melanoma	16/16	100.00%	0.57% (0.12-0.97%)	13 (2-23)
<b>EGFR Ex 19 Deletions (N=2)</b>	7:55242464:AGGAATTAAGAGAAGC:A (E746_A750del), 7:55242465:GGAATTAAGAGAAGCA:G (E746_A750del)	Indels	NSCLC	23/23	100.00%	0.49% (0.14-0.80%)	10 (4-22)
<b>EGFR Exon 20 insertions</b>	7:55248998:A:ATGCCAGCG (V769_D770insASV)	Indels	NSCLC	12/13	92.31%	0.31% (0.13-0.72%)	4 (2-10)
<b>EGFR L858R</b>	7:55259515:T:G (L858R)	SNVs	NSCLC	19/19	100.00%	0.38% (0.13-0.80%)	10 (4-15)
<b>EGFR T790M</b>	7:55249071:C:T (T790M)	SNVs	NSCLC	19/19	100.00%	0.35% (0.11-0.59%)	7 (2-11)
<b>ESR1 D538G</b>	6:152419926:A:G (D538G)	SNVs	Breast	10/10	100.00%	0.27% (0.13-0.46%)	6 (3-11)
<b>IDH1 R132C</b>	2:209113113:G:A (R132C)	SNVs	CHOL	10/10	100.00%	0.40% (0.12-0.77%)	7 (2-12)
<b>KIT D816V</b>	4:55599321:A:T (D816V)	SNVs	GIST	8/10	80.00%	0.46% (0.24-0.69%)	9 (4-13)
<b>KIT SNVs (N=8)</b>	4:55565852:G:T, 4:55569926:G:A, 4:55573299:A:G, 4:55575593:C:T, 4:55593661:T:C (L576P), 4:55594221:A:G (K642E), 4:55602765:G:A, 4:55603391:C:A	SNVs	GIST	50/50	100.00%	0.44% (0.14-0.88%)	7 (2-19)
<b>KIT SNVs (N=8)</b>	4:55565852:G:T, 4:55569926:G:A, 4:55573299:A:G, 4:55575593:C:T, 4:55593661:T:C (L576P), 4:55594221:A:G (K642E), 4:55602765:G:A, 4:55603391:C:A	SNVs	GIST	28/30	93.33%	0.28% (0.12-0.58%)	8 (3-19)
<b>KIT insertions/deletions (N=9)</b>	4:55524240:TC:T, 4:55561938:TTTG:T, 4:55564681:AG:A, 4:55589771:A:ACGATTTT, 4:55592178:C:CTGCCTT, 4:55595617:TATAAGA:T, 4:55597490:CCAG:C, 4:55598133:CA:C, 4:55604631:CAG:C	Indels	GIST	20/20	100.00%	0.39% (0.24-0.68%)	6 (4-16)
<b>KIT insertions/deletions (N=9)</b>	4:55524240:TC:T, 4:55561938:TTTG:T, 4:55564681:AG:A, 4:55589771:A:ACGATTTT, 4:55592178:C:CTGCCTT, 4:55595617:TATAAGA:T, 4:55597490:CCAG:C, 4:55598133:CA:C, 4:55604631:CAG:C	Indels	GIST	64/70	91.43%	0.39% (0.11-1.28%)	6 (2-13)
<b>KRAS G12C/D/V</b>	12:25398284:C:T (G12D)	SNVs	NSCLC, CRC	15/15	100.00%	0.58% (0.30-1.23%)	10 (5-22)
<b>KRAS G13D</b>	12:25398281:C:T (G13D)	SNVs	NSCLC, CRC	10/10	100.00%	0.27% (0.23-0.61%)	5 (4-11)
<b>KRAS K117N</b>	12:25378647:T:G (K117N)	SNVs	NSCLC, CRC	10/10	100.00%	0.48% (0.33-0.64%)	9 (6-11)
<b>KRAS Q61K/H (N=2)</b>	12:25380275:T:G (Q61H), 12:25380277:G:T (Q61K)	SNVs	NSCLC, CRC	16/16	100.00%	0.34% (0.13-0.77%)	6 (2-10)
<b>MET D1246N</b>	7:116423407:G:A (d1246n)	SNVs	NSCLC	10/10	100.00%	0.44% (0.16-0.82%)	8 (3-17)
<b>MET Exon 14 Skipping</b>	7:116412044:G:A (exon_14_skip)	SNVs	NSCLC	10/10	100.00%	0.48% (0.35-0.80%)	9 (6-14)
<b>PDGFRA D842V</b>	4:55152093:A:T (D842V)	SNVs	GIST	10/10	100.00%	0.31% (0.22-0.79%)	6 (4-12)
<b>PIK3CA E545K</b>	3:178936091:G:A (E545K)	SNVs	Breast	27/29	93.10%	0.46% (0.12-0.73%)	8 (2-14)
<b>PIK3CA H1047R</b>	3:178952085:A:G (H1047R)	SNVs	Breast	16/16	100.00%	0.41% (0.13-1.95%)	7 (2-28)
<b>RET SNVs (N=2)</b>	10:43613843:G:A, 10:43617416:T:C (M918T)	SNVs	Thyroid, NSCLC	19/20	95.00%	0.35% (0.18-0.58%)	8 (4-14)
<b>RET insertions/deletions (N=2)</b>	10:43609073:ACTGCTCCCTGAGGAGGAGAAGTGCTT:A, 10:43615611:GAGATGTTATGA:G	Indels	Thyroid, NSCLC	16/20	80.00%	0.29% (0.15-0.73%)	6 (2-10)
<b>ROS1 SNVs (Acquired resistance kinase domain mutations) (N=2)</b>	6:117638347:C:T (G2032R), 6:117639351:C:T	SNVs	NSCLC	20/20	100.00%	0.29% (0.16-0.78%)	7 (4-16)
<b>ROS1 insertions/deletions (Acquired resistance kinase domain mutations)</b>	6:117641138:G:GA	Indels	NSCLC	9/10	90.00%	0.55% (0.24-0.67%)	12 (6-17)
<b>CCDC6-RET</b>	CCDC6 exon 1   RET exon 11	Fusions	N/A	8/8	100.00%	0.30% (0.06-1.29%)	80 (20-170)
<b>CD74-ROS1</b>	CD74 exon 6   ROS1 exon 35	Fusions	N/A	10/10	100.00%	1.08% (0.44-1.98%)	43 (18-60)
<b>EML4-ALK</b>	EML4 exon 13   ALK exon 20	Fusions	N/A	10/10	100.00%	0.16% (0.13-0.42%)	39 (31-64)
<b>NCOA4-RET</b>	NCOA4 exon 7   RET exon 12	Fusions	N/A	18/18	100.00%	0.26% (0.13-0.67%)	40 (24-62)
<b>TPR-ALK</b>	TPR exon 15   ALK exon 20	Fusions	N/A	8/8	100.00%	0.25% (0.13-0.40%)	46 (32-64)

	Alteration type	Gene	Variant	Variant ESCAT description	RecordID	REF	ALT	Relevant tumor type	Reference standard	Spike-in frequency	TP	FP	FN	TN	N variants total	Analytical sensitivity	Observed allele frequency (median and range)	Observed supporting reads (median and range)	All variants	ESCAT Level 1 (all tumor types)	ESCAT Level 1 NSCLC
0	Indels	ALK			229456452:ACA	AC	A		Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.58% (0.14-0.77%)	12 (3-18)	1	0	0
1	Indels	ALK			22949832:TC:T	TC	T		Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.34% (0.15-0.93%)	6 (3-14)	1	0	0
2	Indels	ALK			229541121:GTG	GT	T		Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.36% (0.20-1.04%)	7 (4-21)	1	0	0
3	Indels	ALK			229543663:T:TA	T	TA		Twist cDNA Pan Cancer	0.005	8	0	2	80499	10	80	0.34% (0.10-0.44%)	7 (2-9)	1	0	0
4	Indels	EGFR			7.55271796.CCCGCGAGG.C	CCCGCGAGG	C		Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.39% (0.27-0.55%)	13 (9-18)	1	0	0
5	Indels	EGFR			7.55223031:GTG:T	GTG	T		Twist cDNA Pan Cancer	0.005	9	0	1	80499	10	90	0.39% (0.25-0.54%)	9 (6-10)	1	0	0
6	Indels	EGFR			7.55229231:AGA	AG	A		Twist cDNA Pan Cancer	0.005	9	0	1	80499	10	90	0.37% (0.11-0.83%)	6 (2-10)	1	0	0
7	Indels	EGFR			7.55233067:GTG:T	GT	T		Twist cDNA Pan Cancer	0.005	9	0	1	80499	10	90	0.46% (0.14-0.49%)	10 (3-11)	1	0	0
8	Indels	EGFR			7.55240741:GTG:T	GT	T		Twist cDNA Pan Cancer	0.005	9	0	1	80499	10	90	0.42% (0.16-0.46%)	8 (3-10)	1	0	0
9	Indels	EGFR	E746_A750del	EGFR Ex 19 Deletions	7.55242464:AGGAATAAGAGAAC	AGGAATAAGAGAAC	A	NSCLC	Horizon Multiplex cDNA	0.005	9	0	0	80500	9	100	0.54% (0.21-0.80%)	10 (4-14)	1	1	1
10	Indels	EGFR	E746_A750del	EGFR Ex 19 Deletions	7.55242464:AGGAATAAGAGAAC	AGGAATAAGAGAAC	A	NSCLC	Horizon Structural Multiplex Reference Standard	0.005	4	0	0	80505	4	100	0.38% (0.23-0.63%)	7 (4-12)	1	1	1
11	Indels	EGFR	E746_A750del	EGFR Ex 19 Deletions	7.55242465:GGAATTAAGAGAAC	GGAATTAAGAGAAC	G	NSCLC	Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.38% (0.14-0.64%)	13 (4-22)	1	1	1
12	Indels	EGFR	V769_D770nsASV	EGFR Exon 20 insertions	7.55248998.AATGGCCAGCG	A	ATGGCCAGCG	NSCLC	Horizon Multiplex cDNA	0.005	9	0	0	80500	9	100	0.28% (0.13-0.72%)	4 (2-10)	1	1	1
13	Indels	EGFR	V769_D770nsASV	EGFR Exon 20 insertions	7.55248998.AATGGCCAGCG	A	ATGGCCAGCG	NSCLC	Horizon Structural Multiplex Reference Standard	0.005	3	0	1	80505	4	75	0.54% (0.28-0.62%)	8 (4-9)	1	1	1
14	Indels	ERBB2			17.37883033:GTGCTCCGCGACCTTACAG:T	GTGCTCCGCGACCTTACAG	T		Twist cDNA Pan Cancer	0.005	2	0	8	80499	10	20	0.18% (0.18-0.18%)	3 (3-3)	1	0	0
15	Indels	ERBB2			17.3786636:G:G	G	G		Twist cDNA Pan Cancer	0.005	9	0	1	80499	10	90	0.29% (0.17-0.55%)	6 (4-10)	1	0	0
16	Indels	ERBB2			17.3786636:G:G	G	G		Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.19% (0.13-0.27%)	3 (2-4)	1	0	0
17	Indels	ERBB2			17.3786654:CAAG:C	CAAG	C		Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.34% (0.18-0.49%)	6 (4-11)	1	0	0
18	Indels	ERBB2			17.37872131:GCT:G	GCT	G		Twist cDNA Pan Cancer	0.005	9	0	1	80499	10	90	0.24% (0.12-0.55%)	4 (2-8)	1	0	0
19	Indels	ERBB2			17.37873887:GATGAGGAGGGCGCATGACAGC	GATGAGGAGGGCGCATGACAGC	G		Twist cDNA Pan Cancer	0.005	7	0	3	80499	10	70	0.25% (0.15-0.66%)	3 (2-6)	1	0	0
20	Indels	ERBB2			17.37876051:GTG:T	GT	T		Twist cDNA Pan Cancer	0.005	9	0	1	80499	10	90	0.41% (0.20-0.90%)	10 (5-22)	1	0	0
21	Indels	ERBB2			17.37879795:TTGAT:T	TTGAT	T		Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.39% (0.15-0.53%)	10 (2-22)	1	0	0
22	Indels	ERBB2			17.37882864:GCT:G	GCT	G		Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.39% (0.15-0.64%)	9 (6-10)	1	0	0
23	Indels	ERBB2			17.37882864:GCT:G	GCT	G		Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.37% (0.28-0.83%)	7 (5-18)	1	0	0
24	Indels	ERBB2			17.37883605:TTCTCACTGGCCCTCCGAAAGGGCTCTG:T	TTCTCACTGGCCCTCCGAAAGGGCTCTG	T		Twist cDNA Pan Cancer	0.005	5	0	5	80499	10	50	0.43% (0.23-0.62%)	6 (3-7)	1	0	0
25	Indels	ERBB2			17.37884126:C:CAAG	C	CAAG		Twist cDNA Pan Cancer	0.005	7	0	3	80499	10	70	0.31% (0.21-0.57%)	8 (5-13)	1	0	0
26	Indels	ERBB2	Y772_A775dup		17.3788081A:AGCATAGTGATG	AGCATAGTGATG	A	AGCATAGTGATG	Sens ID 5 plex Positive Control	0.005	6	0	0	80503	6	100	0.77% (0.59-1.15%)	16 (13-25)	1	0	0
27	Indels	ERBB2	Y772_A775dup		17.3788081A:AGCATAGTGATG	AGCATAGTGATG	A	AGCATAGTGATG	Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.24% (0.12-0.42%)	8 (4-13)	1	0	0
28	Indels	FGFR3			4.1801137:GTG:T	GT	T		Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.31% (0.23-1.02%)	6 (4-14)	1	0	0
29	Indels	FGFR3			4.1805481:TAGGAGAGC:T	TAGGAGAGC	T		Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.48% (0.15-0.98%)	7 (2-11)	1	0	0
30	Indels	FGFR3			4.1806550:G:GGTACCA	G	GGTACCA		Twist cDNA Pan Cancer	0.005	9	0	1	80499	10	90	0.30% (0.20-0.78%)	4 (2-11)	1	0	0
31	Indels	FGFR3			4.1808948:C:CGA	C	CGA		Twist cDNA Pan Cancer	0.005	5	0	5	80499	10	50	0.20% (0.20-0.70%)	2 (2-7)	1	0	0
32	Indels	FGFR3			4.1808948:C:CGA	C	CGA		Twist cDNA Pan Cancer	0.005	9	0	1	80499	10	90	0.29% (0.25-0.39%)	7 (6-10)	1	0	0
33	Indels	GN11			19.3114887:CAAC	CA	C		Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.23% (0.11-0.27%)	4 (2-5)	1	0	0
34	Indels	GN11			19.3118333:GTG:T	GT	T		Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.39% (0.25-0.53%)	7 (5-11)	1	0	0
35	Indels	KIT		KIT insertions/deletions	4.5552420:TC:T	TC	T	GIST	Twist cDNA Pan Cancer	0.005	9	0	1	80499	10	90	0.53% (0.28-1.28%)	5 (2-11)	1	0	0
36	Indels	KIT		KIT insertions/deletions	4.5556193:TTG:T	TTG	T	GIST	Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.21% (0.14-0.97%)	3 (2-12)	1	0	0
37	Indels	KIT		KIT insertions/deletions	4.55564681:AGA:A	AGA	A	GIST	Twist cDNA Pan Cancer	0.005	9	0	1	80499	10	90	0.17% (0.12-0.71%)	3 (2-13)	1	0	0
38	Indels	KIT		KIT insertions/deletions	4.55589771:A:ACGATTTT	A	ACGATTTT	GIST	Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.39% (0.25-0.57%)	6 (4-9)	1	1	0
39	Indels	KIT		KIT insertions/deletions	4.5559978:C:CTGCGTT	C	CTGCGTT	GIST	Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.39% (0.24-0.88%)	8 (5-16)	1	1	0
40	Indels	KIT		KIT insertions/deletions	4.5559517:TAGAGATC	T	TAGAGATC	GIST	Twist cDNA Pan Cancer	0.005	9	0	1	80499	10	90	0.60% (0.34-0.91%)	8 (4-10)	1	0	0
41	Indels	KIT		KIT insertions/deletions	4.55597490:CCAG:C	CCAG	C	GIST	Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.44% (0.13-0.72%)	8 (2-9)	1	0	0
42	Indels	KIT		KIT insertions/deletions	4.55598133:CA:C	CA	C	GIST	Twist cDNA Pan Cancer	0.005	9	0	1	80499	10	90	0.56% (0.18-0.83%)	6 (2-9)	1	0	0
43	Indels	KIT		KIT insertions/deletions	4.5560431:CAAG:C	CAAG	C	GIST	Twist cDNA Pan Cancer	0.005	8	0	2	80499	10	80	0.31% (0.11-0.45%)	7 (2-10)	1	0	0
44	Indels	MET			7.116339746:CTCT:C	CTCT	C		Twist cDNA Pan Cancer	0.005	9	0	1	80499	10	90	0.27% (0.12-0.47%)	4 (2-8)	1	0	0
45	Indels	MET			7.11633943:ATTTCAGTCTGG	ATTTCAGTCTGG	A		Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.38% (0.23-0.67%)	6 (4-12)	1	0	0
46	Indels	MET			7.116395509:CTAGAGTCTCTCTGGAAATGAG	CTAGAGTCTCTCTGGAAATGAG	A		Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.48% (0.28-0.65%)	8 (4-12)	1	0	0
47	Indels	MET			7.116398541:ACA:AC	AC	A	AT	Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.42% (0.27-0.83%)	7 (4-15)	1	0	0
48	Indels	MET			7.116399448:GTG:T	GT	T		Twist cDNA Pan Cancer	0.005	9	0	1	80499	10	90	0.19% (0.12-0.58%)	4 (3-11)	1	0	0
49	Indels	MET			7.116403181:C:CA	C	CA		Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.18% (0.14-0.29%)	4 (3-7)	1	0	0
50	Indels	MET			7.11641494:GACATGTCCTCCCA:G	GACATGTCCTCCCA	G		Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.46% (0.25-0.77%)	9 (6-18)	1	0	0
51	Indels	MET			7.116418865:A:ATT	A	ATT		Twist cDNA Pan Cancer	0.005	8	0	2	80499	10	80	0.32% (0.11-0.68%)	5 (2-10)	1	0	0
52	Indels	MET			7.116422110:CA:C	CA	C		Twist cDNA Pan Cancer	0.005	8	0	2	80499	10	80	0.60% (0.30-0.80%)	10 (5-15)	1	0	0
53	Indels	MET			7.116439056:CATGTGCAAGCGCT	CATGTGCAAGCGCT	C		Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.61% (0.17-0.72%)	16 (4-18)	1	0	0
54	Indels	PDGFR A	S566_E571delinsR		4.5514051:GCCCATGATGAGCATGA	GCCCATGATGAGCATGA	G		Twist cDNA Pan Cancer	0.005	8	0	2	80499	10	80	0.54% (0.37-0.79%)	10 (7-13)	1	0	0
55	Indels	PIK3CA			3.118927462:GTG:T	GT	T		Twist cDNA Pan Cancer	0.005	10	0	0	80499	10	100	0.46% (0.16-0.91%)	6 (2-12)	1	0	0
56	Indels	PIK3CA			3.118928078:AGAAGATTGCT																



	<b>NextSeq 2000</b>
<b>Flow Cell</b>	P2
<b>N runs</b>	2
<b>N samples</b>	30
<b>Reads [M]</b>	64.10±8.24
<b>Bases [Gb]</b>	9.68±1.24
<b>Aligned duplex consensus reads [M]</b>	1.28±0.17
<b>Duplex consensus reads aligned on target [%]</b>	95.12±1.58
<b>Mean coverage (duplex consensus reads) - from Prime [x]</b>	910.40±139.91
<b>Fraction of target covered (duplex consensus reads) [%]</b>	100.00±0.00
<b>Coverage evenness [%]</b>	86.27±2.98



<b>Alteration type</b>	<b>Variant subset</b>	<b>Inter-assay concordance</b>	<b>Intra-assay concordance (mean±sd)</b>
<b>SNVs</b>	<b>ESCAT Level I NSCLC</b>	100.00%	100.00±0.00%
	<b>ESCAT Level I (all tumor types)</b>	100.00%	97.16±4.50%
	<b>All variants</b>	96.81%	90.12±10.27%
<b>Indels</b>	<b>ESCAT Level I NSCLC</b>	92.59%	89.42±15.77%
	<b>ESCAT Level I (all tumor types)</b>	94.29%	92.31±12.43%
	<b>All variants</b>	94.93%	90.74±11.75%

	<b>NextSeq 500/550</b>	<b>NextSeq 2000</b>	<b>NovaSeq 6000</b>	<b>All</b>
<b>Flow Cell</b>	Mid-output	P2	SP	
<b>N runs</b>	1	1	1	3
<b>N samples</b>	15	15	15	45
<b>Reads [M]</b>	46.25±7.11	63.10±8.37	68.86±8.45	59.17±12.44
<b>Bases [Gb]</b>	6.89±1.06	9.53±1.26	10.95±1.34	9.07±2.07
<b>Aligned duplex consensus reads [M]</b>	1.06±0.13	1.28±0.17	1.30±0.18	1.21±0.19
<b>Duplex consensus reads aligned on target [%]</b>	95.16±1.49	95.21±1.53	95.31±1.49	95.22±1.50
<b>Mean coverage (duplex consensus reads) - from Prime [x]</b>	752.04±108.16	905.13±139.88	930.52±144.89	861.14±153.42
<b>Fraction of target covered (duplex consensus reads) [%]</b>	100.00±0.00	100.00±0.00	100.00±0.00	100.00±0.00
<b>Coverage evenness [%]</b>	82.79±2.69	86.14±2.91	86.16±3.00	85.02±3.28

Alteration type	Variant subset	Instrument	Number positives / Number expected	Analytical sensitivity	Analytical specificity	Observed VAF (median and range)*	Supporting reads depth (median and range)*
SNVs + Indels	ESCAT Level I NSCLC	NextSeq 550	110/116	94.83%	99.89%	0.40 (0.12-1.20%)	6 (2-22)
		NextSeq 2000	115/116	99.14%	99.86%	0.37 (0.13-1.19%)	8 (2-23)
		NovaSeq 6000	111/116	95.69%	99.83%	0.37 (0.12-1.49%)	8 (2-25)
	ESCAT Level I (all tumor types)	NextSeq 550	160/170	94.12%	99.89%	0.40 (0.11-1.20%)	6 (2-22)
		NextSeq 2000	166/170	97.65%	99.86%	0.37 (0.13-1.19%)	8 (2-23)
		NovaSeq 6000	163/170	95.88%	99.83%	0.37 (0.12-1.49%)	8 (2-25)
	All variants	NextSeq 550	720/862	83.53%	99.89%	0.39 (0.11-1.75%)	6 (2-22)
		NextSeq 2000	785/862	91.07%	99.86%	0.37 (0.11-1.43%)	7 (2-23)
		NovaSeq 6000	774/862	89.79%	99.83%	0.36 (0.11-1.49%)	7 (2-28)
Fusions	All variants	NextSeq 550	38/38	100.00%	100.00%	0.11% (0.05-0.29%)	36 (12-73)
		NextSeq 2000	38/38	100.00%	100.00%	0.11% (0.05-0.29%)	36 (12-73)
		NovaSeq 6000	38/38	100.00%	100.00%	0.11% (0.05-0.29%)	36 (12-73)

<b>Alteration type</b>	<b>Variant subset</b>	<b>Number concordant / Total called variants</b>	<b>Pairwise concordance range</b>	<b>Overall concordance</b>
<b>SNVs + Indels</b>	<b>ESCAT Level I NSCLC</b>	107/116	93.86-96.52%	92.24%
	<b>ESCAT Level I (all tumor types)</b>	156/168	94.05-97.01%	92.86%
	<b>All variants</b>	690/809	87.92-94.15%	85.29%

	<b>NextSeq 1000/2000</b>	<b>NovaSeq 6000</b>	<b>All</b>
<b>Flow Cell</b>	P1/P2	SP	
<b>N runs</b>	4	2	6
<b>N samples</b>	16	20	36
<b>Reads [M]</b>	61.55±10.88	57.74±10.70	59.59±10.95
<b>Bases [Gb]</b>	9.29±1.64	9.18±1.70	9.24±1.67
<b>Aligned duplex consensus reads [M]</b>	1.24±0.22	1.26±0.25	1.25±0.23
<b>Duplex consensus reads aligned on target [%]</b>	94.62±1.81	98.40±1.59	96.62±2.54
<b>Mean coverage (duplex consensus reads) - from Prime [x]</b>	888.00±166.88	931.50±174.59	910.43±172.28
<b>Fraction of target covered (duplex consensus reads) [%]</b>	100.00±0.00	100.00±0.00	100.00±0.00
<b>Coverage evenness [%]</b>	86.34±3.83	80.82±3.26	83.49±4.50

		Spike-in frequency	Analytical sensitivity					
			0.10%	0.25%	0.50%	1.00%	2.50%	5.00%
Alteration type	Variant subset	N variants tested						
SNVs	ESCAT Level I NSCLC	63	31.75%	63.49%	100.00%	98.41%	100.00%	100.00%
	ESCAT Level I (all tumor types)	96	34.38%	61.46%	96.88%	97.92%	100.00%	100.00%
	All variants	393	33.33%	63.10%	93.64%	96.18%	100.00%	100.00%
Indels	ESCAT Level I NSCLC	12	25.00%	83.33%	91.67%	100.00%	100.00%	100.00%
	ESCAT Level I (all tumor types)	18	27.78%	77.78%	94.44%	94.44%	100.00%	100.00%
	All variants	234	23.50%	62.82%	90.60%	93.59%	100.00%	99.57%
Fusions	All variants	27	88.89%	88.89%	100.00%	100.00%	100.00%	100.00%

	<b>NextSeq 500/550</b>	<b>NextSeq 2000</b>	<b>NovaSeq 6000</b>	<b>All</b>
<b>Flow Cell</b>	Mid-output	P2	SP	
<b>N runs</b>	1	1	1	3
<b>N samples</b>	6	3	6	15
<b>Reads [M]</b>	50.39±3.02	74.76±3.67	59.17±9.20	58.77±10.97
<b>Bases [Gb]</b>	7.51±0.45	11.29±0.55	9.41±1.46	9.02±1.74
<b>Aligned duplex consensus reads [M]</b>	1.14±0.28	1.53±0.09	1.00±0.21	1.17±0.30
<b>Duplex consensus reads aligned on target [%]</b>	95.84±0.38	97.65±0.07	96.99±1.04	96.65±1.00
<b>Mean coverage (duplex consensus reads) - from Prime [x]</b>	778.95±210.38	1116.63±62.68	722.36±166.70	826.03±227.95
<b>Fraction of target covered (duplex consensus reads) [%]</b>	100.00±0.00	100.00±0.00	100.00±0.00	100.00±0.00
<b>Coverage evenness [%]</b>	85.58±1.27	81.34±0.19	83.93±2.96	84.08±2.56

			Analytical sensitivity				
		Input cfDNA	10 ng	20 ng	25 ng	30 ng	50 ng
Alteration type	Variant subset	N variants tested					
SNVs	ESCAT Level I NSCLC	51	98.04%	94.12%	94.12%	100.00%	96.08%
	ESCAT Level I (all tumor types)	78	91.03%	94.87%	96.15%	98.72%	94.87%
	All variants	372	87.37%	92.47%	93.55%	90.32%	94.62%
Indels	ESCAT Level I NSCLC	12	91.67%	91.67%	100.00%	100.00%	100.00%
	ESCAT Level I (all tumor types)	18	88.89%	94.44%	100.00%	100.00%	100.00%
	All variants	231	83.98%	93.51%	94.81%	91.34%	92.64%
Fusions	All variants	27	92.59%	100.00%	100.00%	100.00%	100.00%



Proficiency test	Sample	Expected result (Gene:Transcript:Exon:cDNA:Protein)	Expected VAF - Lead institutes	Observed VAF - Hedera HP2
QuIP ESR1	1	ESR1:NM_000125:Exon 8:c.1610A>C:p.(Tyr537Ser)	2.60%	1.36%
	2	ESR1:NM_000125:Exon 8:c.1609T>A:p.(Tyr537Asn)	3.20%	2.21%
		ESR1:NM_000125:Exon 5:c.1138G>C:p.(Glu380Gln)	1.20%	2.60%
	3	ESR1:NM_000125:Exon 8:c.1607T>A:p.(Leu536His)	1.60%	2.10%
	4	ESR1:NM_000125:Exon 8:c.1610A>G:p.(Tyr537Cys)	1.50%	2.05%
		ESR1:NM_000125:Exon 5:c.1138G>C:p.(Glu380Gln)	7.10%	7.41%
	5	Wildtype	Wildtype	Wildtype
	6	ESR1:NM_000125:Exon 8:c.1613A>G:p.(Asp538Gly)	1.40%	2.73%
	7	ESR1:NM_000125:Exon 5:c.1138G>C:p.(Glu380Gln)	1.40%	1.48%
	8	ESR1:NM_000125:Exon 8:c.1609T>A:p.(Tyr537Asn)	1.60%	1.30%
9	ESR1:NM_000125:Exon 8:c.1607T>G:p.(Leu536Arg)	1.30%	1.96%	
10	ESR1:NM_000125:Exon 8:c.1610A>G:p.(Tyr537Cys)	1.30%	2.28%	
QuIP METex14	1	MET:NC_000007.13(NM_001127500.3):c.2942-26_2942-10del	N/A	2.20%
	2	MET:NC_000007.13(NM_001127500.3):c.3082G>C	N/A	2.44%
	3	MET:NC_000007.13(NM_001127500.3):c.2942-18_2942-5del	N/A	8.16%
	4	Wildtype	N/A	Wildtype
	5	MET:NC_000007.13(NM_001127500.3):c.3082+1G>T	N/A	1.49%
	6	MET:NC_000007.13(NM_001127500.3):c.2942-18_2942-5del	N/A	1.53%
	7	Wildtype	N/A	Wildtype
	8	MET:NC_000007.13(NM_001127500.3):c.3082G>C	N/A	4.50%
	9	MET:NC_000007.13(NM_001127500.3):c.2942-26_2942-10del	N/A	6.30%
	10	MET:NC_000007.13(NM_001127500.3):c.3082+1G>T	N/A	5.23%

	NextSeq 500/550	NextSeq 500/550.1	NextSeq 1000/2000	NovaSeq 6000	All
<b>Flow Cell</b>	High-output	Mid-output	P2	SP	
<b>N runs</b>	1	10	2	3	16
<b>N samples</b>	16	47	9	65	137
<b>Reads [M]</b>	45.12±6.11	45.14±12.42	60.41±9.84	53.22±21.39	49.98±17.43
<b>Bases [Gb]</b>	6.65±0.90	6.71±1.85	9.12±1.49	7.96±3.18	7.46±2.61
<b>Aligned duplex consensus reads [M]</b>	1.15±0.20	1.15±0.32	1.36±0.50	1.29±0.57	1.23±0.46
<b>Duplex consensus reads aligned on target [%]</b>	93.03±1.92	94.77±1.78	92.21±2.29	93.48±2.74	93.79±2.46
<b>Mean coverage (duplex consensus reads) - from Varis [x]</b>	814.00±153.01	822.34±234.10	949.22±372.69	911.66±394.54	872.08±326.94
<b>Mean coverage on exons relevant for NSCLC ESCAT Level 1 SNVs/Indels (duplex consensus reads) [x]</b>	977.38±198.11	1020.46±296.65	1379.47±1004.90	1090.93±468.94	1072.45±462.37
<b>Fraction of target covered (duplex consensus reads) [%]</b>	100.00±0.00	99.96±0.11	99.99±0.02	100.00±0.00	99.99±0.07
<b>Coverage evenness [%]</b>	81.26±3.09	79.37±4.19	72.83±9.85	82.52±6.09	80.65±6.12

ESCAT Level 1 variant	ESCAT cancer type	Number agreeing / Total	Concordance	Observed VAF (median and range)
<b>ALK SNVs (Acquired resistance kinase domain mutations)</b>	NSCLC	2/2	100.00%	17.98% (0.14-35.81%)
<b>BRAF V600E</b>	NSCLC, CRC, Melanoma	4/5	80.00%	0.80% (0.20-29.63%)
<b>EGFR C797S</b>	NSCLC	2/2	100.00%	1.34% (0.90-1.77%)
<b>EGFR Ex 19 Deletions</b>	NSCLC	28/29	96.55%	3.36% (0.11-67.57%)
<b>EGFR Exon 20 insertions</b>	NSCLC	2/2	100.00%	39.79% (3.83-75.75%)
<b>EGFR G719S</b>	NSCLC	1/1	100.00%	0.87% (0.87-0.87%)
<b>EGFR L858R</b>	NSCLC	14/16	87.50%	5.36% (0.16-74.26%)
<b>EGFR L861Q</b>	NSCLC	2/2	100.00%	4.24% (2.83-5.65%)
<b>EGFR S768I in exon 20</b>	NSCLC	1/1	100.00%	1.22% (1.22-1.22%)
<b>EGFR T790M</b>	NSCLC	3/4	75.00%	1.32% (1.30-4.07%)
<b>ESR1</b>	Breast	11/14	78.57%	0.76% (0.18-58.21%)
<b>ESR1</b>	Breast	2/3	66.67%	2.97% (1.02-4.93%)
<b>KRAS G12C/D/V</b>	NSCLC	5/5	100.00%	0.41% (0.13-4.68%)
<b>KRAS G12C/D/V</b>	NSCLC, CRC	10/11	90.91%	4.92% (1.43-53.34%)
<b>KRAS G13D</b>	NSCLC, CRC	1/1	100.00%	4.19% (4.19-4.19%)
<b>KRAS Q61K/H</b>	NSCLC, CRC	6/6	100.00%	3.00% (0.37-24.49%)
<b>MET Exon 14 Skipping</b>	NSCLC	1/1	100.00%	11.30% (11.30-11.30%)
<b>PIK3CA E542K</b>	Breast	4/4	100.00%	1.18% (0.35-14.93%)
<b>PIK3CA E545K</b>	Breast	5/7	71.43%	1.01% (0.15-14.27%)
<b>PIK3CA H1047R</b>	Breast	4/4	100.00%	14.98% (0.61-53.11%)

<b>Sample ID</b>	<b>cfDNA Input amount (ng)</b>	<b>Variant</b>	<b>Expected VAF%</b>	<b>Observed VAF%</b>
<b>Sample 42 (from Supplementary Table S3)</b>	<b>30 ng</b>	EGFR T790M	2.10%	1.32%
		EGFR L858R	12.70%	12.63%
	<b>20 ng</b>	EGFR T790M	-	1.38%
		EGFR L858R	-	10.40%
	<b>10 ng</b>	EGFR T790M	-	1.88%
		EGFR L858R	-	10.68%

Sample ID	Variant	Input ng Other Vendor	Observed VAF% Other Vendor	Input ng HP2	Observed VAF% HP2
Sample 8	BRAF K601E	37.7 ng	0.60%	13.3 ng	0.86%
Sample 22	BRAF K601E	33.7 ng	0.11%	21.7 ng	0.34%
Sample 10	EGFR E746_A750del	73.7 ng	0.44%	40.0 ng	0.75%
Sample 13	PIK3CA E545K	58.6 ng	0.20%	40.0 ng	1.01%
Sample 14	EGFR S768I	52.8 ng	0.60%	40.0 ng	1.22%
	PIK3CA H1047R		1.70%		3.69%
Sample 39	EGFR E746_A750del	100.0 ng	3.40%	30.0 ng	2.85%
	KRAS K117N		not detected		0.15%
Sample 9	KRAS G12F	73.7 ng	1.13%	40.0 ng	1.43%
Sample 17	KIT Y578H	100.0 ng	1.20%	40.0 ng	3.77%
	BRAF K499E		1.70%		3.78%
	KRAS G13D		1.00%		4.19%
	KRAS A146T		not detected		0.48%
Sample 12	NRAS I55V	100.0 ng	3.60%	40.0 ng	2.11%
Sample 16	PIK3CA E542K	36.8 ng	0.62%	35.0 ng	1.20%
Sample 19	EGFR E746_A750del	100.0 ng	8.20%	40.0 ng	8.18%
	EML4-ALK fusion		not detected in LbX kit but confirmed in tissue		0.17%

<b>Sample type</b>	<b>Cancer type</b>	<b>Orthogonal MSI status</b>	<b>Predicted MSI status</b>	<b>Count</b>	<b>Unique</b>
FFPE	CRC	MSI-high	MSI-high	7	5
FFPE	CRC	MSS	MSI-high	1	1
FFPE	CRC	MSS	MSS	2	2
FFPE	Endometrial	MSI-high	MSI-high	2	2
FFPE	Endometrial	MSS	MSS	3	3
FFPE	NSCLC	MSS	MSS	5	5
FFPE	other	MSS	MSS	7	7
cfDNA	CRC	MSI-high	MSI-high	4	3
cfDNA	CRC	MSS	MSS	2	2
cfDNA	Endometrial	MSI-high	MSI-high	1	1
cfDNA	NSCLC	MSS	MSS	43	37
cfDNA	other	MSS	MSS	1	1